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1. Introduction 
Vasculogenesis is the vascular formation process initiated from endothelial 
progenitor cells, which implicates in both embryonic and postnatal development (1; 2). 
At the beginning of the embryonic stage, vascular formation is essential for composing a 
functional circulatory system to support the supply of oxygen and nutrition, and the 
removal of metabolic wastes (3; 4). During the postnatal stage, vascular formation can 
be induced through mobilizing in situ or transplantation of endothelial progenitor cells to 
provide vital novel-vascular connections after ischemic diseases or tissue injuries (5; 6). 
Due to the importance of vascular formation in development, dysfunction or 
dysregulation of vasculogenesis would lead to severe pathological effects including 
ischemic diseases, immune disorders, and tumorigenesis (7; 8). Therefore, in this thesis 
we focus on studying the signaling pathways involved in regulating vasculogenesis. One 
of the potential candidates is the arachidonic acid (AA)/leukotriene (LT) signaling 
pathway that is generated by fully-differentiated immune cells. To study vasculogenesis 
and leukocyte differentiation, we used embryoid bodies (EBs) differentiated from 
embryonic stem (ES) cells as in vitro model. 
 
 
1.1 Stem cells 
Stem cells regardless of their sources are considered as undifferentiated cells with 
three common properties: proliferation, self-renewal and the ability to differentiate into 
different specialized cell types in vitro and in vivo (9). Proliferation is a consecutive 
procedure resulting in the physical division of the cells (10). Self-renewal, the key 
process to ensure the cell to remain undifferentiated over long periods of time through 
keeping cell cycle progression, is the key procedure to generate more stem cells (11; 
12).  The characteristics of stem cells to differentiate into cells of the three germ layers 
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make them suitable to replace defective cells or tissues. This can be used as a 
therapeutic strategy to cure diseases, e.g. to enhance injured rat spinal cord recovery 
by stem cell transplantation (13). Depending on the differentiation potential, stem cells 
can be subdivided into totipotent stem cells, pluripotent stem cells and multipotent stem 
cells (Figure 1.1). 
 
 
Figure 1.1 Development of ES cell. The ES cells have the potency to develop into 
different cell types of the body. 
 
Totipotent stem cells are able to differentiate into any cell type that further 
becomes an individual. After fertilization, an egg begins to differentiate from the 2-cell 
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stage to the 4-cell stage and then the 8-cell stage (14). During these periods of time the 
fertilized eggs are totipotent cells, which then develop into blastocysts containing 
pluripotent stem cells (15; 16). A human fertilized egg takes typically 4 to 5 days to form 
a blastocyst and a mouse fertilized egg takes 3.5 days.  
 
Pluripotent stem cells are able to differentiate into all cell types of the three germ 
layers, endoderm, ectoderm and mesoderm (Figure 1.2). The three germ layers 
continue to develop an organism. The pluripotent stem cells can further be divided into 
three types: ES cells, embryonic germ (EG) cells, and embryonic carcinoma (EC) stem 
cells (17). 
 
 
Figure 1.2 Development of pluripotent stem cells. Pluripotent stem cells can 
differentiate into the three germ layers. 
 
Multipotent stem cells, also known as adult stem cells, have the same feature of 
self-renewal and possess the ability to differentiate into limited cell types. Adult stem 
cells exist in the tissues and organs inside adult individuals such as bone marrow, heart, 
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liver and neurons (18-20). They are capable of replacing, regenerating and repairing the 
injured tissues to maintain the function of the tissues and organs (21).  
 
Embryonic stem cells 
Pluripotent ES cells, which are derived from the inner cell mass of blastocysts, can 
be cultured for long periods of time in vitro (15). There are several stem cell markers 
expressed in ES cells such as octamer-binding transcription factor 4 (Oct 4), signal 
transducer and activator of transcription 3 (STAT-3), stage-specific embryonic antigen 
(SSEA)-1, alkaline phosphatase (AP), sex determining region Y-box 2 (Sox2), Nanog, 
kruppel-like factor 4 (Klf4), CD34, CD133,  and ATP-binding cassette sub-family G 
member 2 (ABCG2) (22-27). Thus the detection of these makers in cells indicates the 
capabilities of self-renewal and pluripotency. 
 
The establishment of pluripotent stem cell lines, which are obtained directly from 
the inner cell mass of mouse blastocysts, can be traced back to 1981 (28). In order to 
maintain the ES cells undifferentiated, they are either co-cultured with inactivated 
mouse fibroblasts or on plates coated with gelatin, and treated with medium containing 
the cytokine leukemia inhibitory factor (LIF) (29-31). LIF, a member of the interleukin 
(IL)-6 cytokine family, is considered a pivotal player for maintaining the ES cells 
undifferentiated (32). LIF has two isoforms, diffusible form (D-LIF) and extracellular 
matrix–bound form (M-LIF), with discriminative properties (33). LIF regulates the Janus 
kinase (JAK)/STAT-3 and the mitogen-activated protein (MAP) kinase pathway via its 
cell surface receptor complex composed of glycoprotein 130 (gp130) and low-affinity 
LIF receptor (LIFR). The tyrosine resident of gp130 is in charge of STAT-3 activation 
for maintaining ES cell self-renewal (34-36). When ES cells reach about 75% 
confluence, the LIF medium is removed and then the ES cells stop self-renewing and 
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initiate differentiation into EBs (37). 
 
In addition to LIF other factors have been reported to maintain the pluripotency and 
self-renewal of ES cells, for instance, transcription factors Oct4, Sox2, and Nanog (38). 
Moreover, the Wnt/-catenin signaling pathway can also determine the fate of ES cells 
toward either differentiation or self-renewal (39). The Wnt signaling pathway leads to 
opposite results through coupling of the Wnt proteins and the Frizzled family receptor 
(40). Some of the studies have demonstrated that the Wnt signaling pathway in ES cells 
promotes both mesoderm and endoderm development. On one hand, the Wnt signaling 
pathway induces higher expression of the mesodermal and endodermal markers, 
Brachyury-T, fetal liver kinase 1 (Flk-1), forkhead box protein A2  (Foxa2), LIM 
homeobox 1 (Lhx1), and alpha-fetoprotein (AFP) in ES cells and thus promotes 
differentiation (41). On the other hand, the Wnt signaling pathway participates in 
pluripotency maintenance by regulating the expression of Oct4, Nanog, and Sox2. 
Previous studies also showed that short-term treatment of Wnt or blockade of -catenin 
can trigger ES cell self-renewal (38; 42).  
 
 
1.2 Leukotriene signaling pathway 
LTs were first discovered in 1938 in lung as "slow reacting substance" (SRS) or 
"slow reacting substance of anaphylaxis" (SRS-A). Later in 1979, the name of LTs was 
given due to their production by leukocytes (43). LTs are generated after immunological 
and nonimmunological stimulation from leukocytes, macrophages, and mastocytoma 
cells, which have effects on respiratory, immune and gastrointestinal systems (44). 
Moreover, LTs, which are derived from AA by 5-lipoxygenase (5-LO), are inflammatory 
lipid mediators. Under pathological conditions, LTs launch the proinflammatory signal 
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through activating cell-surface protein G-bound receptors and lead to changes of 
intracellular calcium, intracellular cyclic adenosine monophosphate (cAMP), or 
diacylglycerol levels (45). Recent studies have reported that LTs are involved in 
cardiovascular disease, asthma, cancer occurrence and fibrosis (46-48). For example, 
LTs are considered as mediators in asthma, in which the cysteinyl leukotrienes (CysLTs) 
regulate pathological signaling pathways of asthma through CysLT receptor 1 
(CysLT1-R) (49). Therefore, LTs inhibitors are generally prescribed as medical treatment 
for asthma, atherosclerosis and chronic inflammatory diseases (50). 
 
 
Figure 1.3 Cellular metabolism of AA. The figure is modified from https:// 
www.caymanchem.com/app/template/landing,EIALeukotrieneResearch.vm;jsessionid=
EEAEFB409423347FDE326280AABDD091 
 
Biological effects of arachidonic acid 
AA is a 20-carbon polyunsaturated omega-6 essential fatty acid, which can be 
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synthesized in humans from dietary linoleic acid. Inside the body, AA plays a role in cell 
membrane fluidity and membrane enzyme activities (51). Originally derived from 
membrane phospholipids through enzymatic reactions carried out by cytosolic 
phospholipase A2 (cPLA2), AA can be further converted to eicosanoids. The 
four cis double bonds of AA influence AA cooperation with oxygen molecules and then 
initiate downstream signaling pathway via the oxygenases cyclooxygenase (COX), 
lipoxygenase (LO), or cytochrome P450 (Figure 1.3) (52-54).  
 
Through production of a variety of derivatives, AA involves in several 
inflammation-related responses. For instance, AA takes part in the innate immune 
system through the AA-derivatives prostaglandins, thromboxanes and LTs (48; 49). 
Among these AA metabolic pathways, we focused in our study on the LO signaling 
pathway, especially the 5-LO pathway. The 5-LO has been found to be commonly 
expressed in the cardiovascular system (55). In addition, products from the 5-LO 
signaling pathway have been reported to play a role in vasculogenesis of ES cells (56; 
57). 
 
Leukotriene synthesis 
LTs can be divided into leukotriene B4 (LTB4) and CysLTs including leukotriene C4 
(LTC4), leukotriene D4 (LTD4) and leukotriene E4 (LTE4) (Figure 1.3). Synthesis of LTs 
begins with the activation of cPLA2 which hydrolyzes endogenous AA from membrane 
phospholipids followed by translocation of 5-LO and free AA to the nuclear membrane in 
response to extracellular stimuli (58). Engaged with 5-lipoxygenase activating protein 
(FLAP), AA can be presented to 5-LO and then be converted into 
5-hydroperoxyeicosatetraenoic acid (5-HPETE), and the subsequent intermediate 
leukotriene A4 (LTA4) (59; 60). Unstable LTA4 can further form LTB4 by reaction catalyzed 
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by LTA4 hydrolase. LTA4 is unstable since the epoxide in C5 and C6 can be conjugated 
with glutathione through glutathione S-transferase -- LTC4 synthase, to form LTC4. 
LTB4 and LTC4 are transported to the extracellular space where LTC4 can again rapidly 
be converted to LTD4 by removing the glutamic acid through gamma-glutamyl 
transpeptidase: LTD4 can be further converted to LTE4 by glycine removal (61; 62). 
 
5-lipoxygenase and 5-lipoxygenase-activating protein 
5-LO, a key enzyme involved in the signaling pathway of LT synthesis, is one of the 
human lipoxygenases principally expressing in leukocytes including neutrophils, 
eosinophils, monocytes/macrophages, mast cells, B-lymphocytes and dendritic cells 
(50). 5-LO is a monomeric enzyme composed of 672 or 673 amino acids, which 
comprises an N-terminal -sandwich and a C-terminal catalytic domain containing the 
prosthetic iron. The enzymatic activity of 5-LO is regulated through phosphorylation of 
serine (Ser) residues, Ser-271, Ser-633, and Ser-523, by kinases such as protein 
kinase A and C (63). 
 
 As an activator of 5-LO, membrane-integrated FLAP is as essential as 5-LO for LT 
synthesis. Although FLAP promotes LT synthesis, it itself has no enzymatic activity. Both 
5-LO and FLAP are expressed in several types of cells, especially in 
bone-marrow-derived cells including eosinophils, neutrophils and mast cells (64). 
Additionally, recent studies have suggested that FLAP is more critical in CysLTs 
synthesis than LTB4 in human Mono Mac 6 cells (65). 
 
Leukotriene B4 and receptors 
 LTB4 (5 [S], 12 [R]-dihydroxy-6, 14-cis-8, 10-trans-eicosatetraenoic acid) was first 
recognized as a regulator of neutrophils and is synthesized under the regulation of 
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several inflammatory mediators such as endotoxin, tumor necrosis factor and 
interleukins (66). Mostly found in polymorphonuclear neutrophils (PMNs), LTA4 is 
converted into LTB4 to mediate neutrophil-dependent microvascular permeability and 
promotes bronchial, gastrointestinal, and vascular smooth muscle contraction in vivo 
(67; 68). Furthermore, LTB4 can regulate the movement of leukocytes both in vivo and in 
vitro (62). By means of the nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFB) and activator protein 1 (AP1) signaling pathway, LTB4 induces synthesis of 
various proinflammatory cytokines such as IL-6, IL-8, tumor necrosis factor(TNF) 
and fibroblast growth factor (FGF) to promote inflammatory-related responses including 
causation of pain as well as proliferation and differentiation of stem cells (69-73). Thus, 
LTB4 is considered as a chemoattractant in several inflammatory and allergic disorders 
such as asthma, allergic rhinitis and allergic conjunctivitis (74). 
 
 LTB4 initiates the following signaling pathway through binding to respective 
receptors including peroxisome proliferator-activated receptor alpha (PPAR), LTB4 
receptor-1 (BLT1) and LTB4 receptor-2 (BLT2). After LTB4 binding, activated PPARα 
induces the signaling cascade by conjugating with PPAR responsive elements to 
facilitate degradation of fatty acids. Hence, activated PPARα could conversely 
down-regulate the lipid mediators derived from AA, i.e. LTB4, through promoting 
degradation, and thus relieve inflammation (75; 76). The other two LTB4 receptors, BLT1 
and BLT2, are cell-surface G-protein coupled receptors. BLT1, which is activated by 
LTB4, is predominantly expressed in leukocytes, smooth muscle cells as well as 
endothelial progenitor cells and has higher affinity for LTB4. BLT2, which is activated not 
only by LTB4 but also by several other hydroxyeicosotetraenoic acids (HETEs), is 
ubiquitously expressed and has lower affinity for LTB4 (77; 78). Despite the different 
expression patterns and affinities, activation of BLT1 and BLT2 receptors by LTB4 
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binding can both result in cell proliferation, differentiation and migration (79). Through 
binding to BLT1 or BLT2 receptors, LTB4 initiates several intracellular signaling 
pathways such as intracellular calcium mobilization, extracellular signal-regulated 
kinase 1 and 2 (ERK1, 2) activation and inflammatory protein generation in 
inflammatory cells (77; 78).  
 
CysLTs and Cys receptors  
 First found in leukocytes, LTA4-derived CysLTs are converted to other downstream 
products including LTC4, LTD4 and LTE4. The structure of LTC4 includes cysteine and 
three conjugated double bonds. Within the LT synthesis pathway, LTC4 is firstly 
transformed to LTD4 and subsequently to LTE4 the most stable CysLT that can exist for 
longer periods of time after synthesis (43; 80). However, LTE4 has lower binding affinity 
to corresponding cell surface receptors (81). Like LTB4, CysLTs also involve in 
inflammatory disorders and responses by directly or in directly inducing leukocyte 
movement (80).  
 
In order to function as lipid mediators of inflammation, CysLTs bind to cell surface 
G-protein-coupled receptors, CysLT1-R or CysLT receptor 2 (CysLT2-R), and trigger 
various downstream signaling pathways depending on different cell types (82; 83). Both 
of the receptors are expressed on immune cells, e.g. basophils, eosinophils, mast cells, 
and macrophages. CysLT1-R is also commonly expressed in structural cells such as 
airway smooth muscle cells, epithelial, and endothelial cells. Compared to all CysLTs, 
LTC4 has the higher affinity toward CysLT2-R than CysLT1-R, and LTD4 has the highest 
affinity to both CysLT-Rs (49). 
 
 
 11 
1.3 Vasculogenesis and angiogenesis 
Blood vessel formation is an essential event during early stages of development 
from embryos, which establishes vessel networks to support nutrition and oxygen 
supply as well as waste removal. Accordingly, dysregulation of the vasculogenic 
process can contribute to various pathological conditions including tumorigenesis (84). 
There are two steps for vascular establishment: it first begins with vasculogenesis and 
then follows by angiogenesis, both of which require Notch signaling pathway for 
initiation (85-87). 
 
Vasculogenesis 
Vasculogenesis, also known as new vascular formation, refers to the process of 
endothelial precursor cells developing de novo vessels from the mesoderm (88; 89). 
Vasculogenesis starts with the differentiation of endothelial precursor cells specified 
from mesoderm, and can be regulated by FGF2 and bone morphogenetic protein (BMP) 
(90; 91). Depending on various genetic regulations, the heterogeneous endothelial cells 
can differentiate into arterial, venous, hemogenic or lymphatic vessels, respectively, 
during vasculogenesis. In adult, endothelial precursor cells are derived from bone 
marrow cells and can participate in vasculogenesis (6). To regulate vasculogenesis, 
several signaling pathways are involved, for instance FGF and vascular endothelial 
growth factor (VEGF) mediated pathways (92). To initiate vasculogenesis, FGFs first 
induce angioblasts from the mesoderm to differentiate into endothelial cells, and then 
initiate branching from the tip of the branchless endothelial cells (93). The ends of these 
cells continue the branching process further until forming a new vascular structure (94). 
On the other hand, VEGF modulates vasculogenesis through binding to one of the two 
high-affinity tyrosine kinase receptors, vascular endothelial growth factor receptor-1 
(VEGFR1) and vascular endothelial growth factor receptor-2 (VEGFR2) (95). VEGFR2, 
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also named Flk-1, is one of the markers of endothelial cells, which is expressed early 
during differentiation and is involved in the regulation of migration, proliferation and 
survival of endothelial cells (87). VEGFR1 and VEGFR2 activation lead to increasing 
levels of Notch1 and its ligand, Delta like ligand 4 (DII4), to establish the vessel 
structures (94). To further determine whether endothelial cells differentiate into arterial 
or venous cells, sonic hedgehog (SHH) plays an important role in mediating the 
expression of VEGF. While SHH-increases the expression of VEGF and prompts 
endothelial cells developing into the arteries, the lower expression of VEGF leads to 
venous development (96).  
 
According to previous studies, vasculogenesis can occur not only 
intraembryonically, but also extraembryonically. These two types of vasculogenesis are 
independent of each other (97). Extraembryonic vasculogenesis takes place in the yolk 
sac blood islands while intraembryonic vasculogenesis occurs inside the developing 
embryo (98). The allantoic bud was discovered as a place generating vascular 
endothelial progenitor cells and hematopoietic progenitor cells as well as the place 
where vasculogenesis takes place (99). During extraembryonic vasculogenesis, 
endodermal cells promote mesodermal cells to initiate blood vessel formation. 
Hemangioblasts migrate together to form the blood islands around which the cells can 
further differentiate into vessels, whereas the cells inside differentiate into blood cells. 
The surrounding cells differentiate initially into angioblasts and then into endothelial 
cells (87). 
 
Angiogenesis 
Angiogenesis refers to the process that extends new vessels from existing vessels 
through endothelial cell sprouting triggered by shortage of nutrition and oxygen supply 
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(100). Higher concentrations of VEGF result from lack of nutrition and oxygen supply 
and promote DII4 binding to corresponding receptors to activate Notch signaling 
pathway and subsequent sprouting of endothelial cells (89; 101). The sprouting process 
is initiated by extended filopodia of tip cells scanning the environment and then 
conducting the vessel formation and growth in the certain direction. The process is first 
initiated by migration of tip cells arising from existing blood vessels; then it is continued 
with the conversion of other endothelial cells directly behind the migrating tip cells into 
stalk cells; finally the process is completed with basement membrane establishment, 
during which cells behind the stalk cells differentiate into phalanx cells and form the 
lumen in the new vessels (89; 102; 103). As a pivotal process in new vessel formation, 
angiogenesis takes place in female adults during menstrual cycle or in adults during 
wound repair. Dysregulated angiogenesis is associated with many diseases, such as 
ischemia-related disorders and tumorigenesis (104). 
 
Notch signaling pathway 
Notch signaling (Figure 1.4) is a critical pathway that mediates endothelial cell 
differentiation to form vessel-like structures. The Notch signaling pathway consists of 
four receptors - Notch1, Notch2, Notch3 and Notch4 - and five ligands - Jagged1, 
Jagged2, Dll1, DII3, and DII4 (94). Among those receptors, Notch 1 and Notch 4 are 
specifically involved in activating the blood vessel formation process, while DII4 is the 
most important Notch ligand for inducing both vasculogenesis and angiogenesis (105). 
Due  to  its  significance  in  blood  vessel formation,  defects of  the Notch  
signaling  pathway would lead to insufficient vascular formation, vessel degeneration 
and abnormal vessel remodeling resulting in embryonic death (106; 107). 
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Figure 1.4 Notch signaling pathway regulates the differentiation of tip cells and 
stalk cells. 
 
 
1.4 Leukocyte differentiation 
Inflammation is a rapid pathological and physiological response to injury and 
pathogen infection in the cells and tissues inside the body, and induces new vascular 
formation (angiogenesis), immune cell proliferation as well as leukocyte migration in the 
influenced cells and tissues (108; 109). To accomplish the inflammatory response, 
proinflammatory mediators like cytokines and chemokines are generated to initiate the 
early response of inflammation. Moreover, cytokines and chemokines are also required 
for communicating immune responses to promote or reduce inflammation (110; 111). 
LTs are one kind of important proinflammatory mediators and are formed by leukocytes, 
macrophages, granulocytes and other cells at the very beginning of the inflammatory 
response (112; 113). Due to the high expression of 5-LO and FLAP in leukocytes, LTs 
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were named after the primary production origin – leukocyte – as leukotrienes (43). LT 
generation varies according to different types of leukocytes. For example, LTB4 is 
mostly produced by neutrophils, while CysLTs are mainly produced by eosinophils, mast 
cells, and basophils; moreover, both of them can be produced by macrophages and 
dendritic cells (49).  
 
Leukocytes participate in the anti-infectious and inflammatory responses, which 
can be divided into granulocytes, i.e. neutrophils, eosinophils and basophils as well as 
agranulocytes, i.e. lymphocytes, monocytes and macrophages (114; 115). Natural killer 
cells, neutrophils, eosinophils, basophils, macrophages and dendritic cells are pivotal 
players in the innate immune system, which acts as the first barrier and fast defensive 
mechanism towards foreign pathogens in an antigen-independent manner that 
recognizes the pathogens directly through pathogen-associated molecular patterns 
(116). On the other hand, B lymphocytes (B cells) and T lymphocytes (T cells) are major 
players in the adaptive immune system. They recognize foreign antigens through 
specific molecular structures such as T-cell receptors (117; 118). 
 
The differentiation of leukocytes begins with hematopoietic stem cells derived from 
blastocysts, which are stored in the hematopoietic stem cell (HSC) niche within the bone 
marrow to maintain the undifferentiated state and self-renewing capacity (119; 120). 
Leukocyte differentiation can be regulated by intrinsic signals. For example, the clonal 
level of HSCs determines the commitment and self-renewal decisions of HSCs through 
intrinsic mechanisms that pre-program the behavior of HSCs, such as their size and 
aging (121). Additionally, leukocyte differentiation can be triggered by environmental 
signals. Whenever pattern-recognition receptors such as toll-like receptors recognize 
foreign pathogens, signals from the activated immune system can lead to differentiation 
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of HSCs into leukocytes, which in turn further facilitates the immune response (122). 
 
 
1.5 Calcium  
Calcium is a necessary mineral for human bodies, especially for maintaining the 
development of bones and teeth. Calcium also plays a role in blood clotting formation, 
muscle contraction and acts as a secondary messenger during neuronal signal 
transduction (123; 124). In addition, calcium intervenes in regulating proliferation, 
development and differentiation of neuronal cells as well as endothelial progenitor cells 
(125; 126). Based on the sources calcium can be divided into extracellular calcium and 
intracellular calcium. Extracellular calcium moderates hormone secretion through 
conjugating with a G protein-coupled calcium-sensing receptor, while intracellular 
calcium moderates hormone secretion through activating phospholipase C and PLA2 
signaling pathways (127). Recent studies have provided evidence that endothelial cell 
functions are closely associated with the intracellular calcium concentration. For 
example, intracellular calcium concentration can be induced for supporting proliferation, 
tubulogenesis and endothelial colony forming cells in response to VEGF (128). The two 
main stores of intracellular calcium are the endoplasmic reticulum and the mitochondria 
(129). 
 
 Previous studies have also demonstrated that calcium involves in regulating the LT 
synthesis pathway. High concentrations of both extracellular and intracellular calcium 
induce PLA2 activation and then enhance AA production (127). Furthermore, 
up-regulated intracellular calcium has been reported to promote 5-LO activation and 
translocation from the cytosol into nuclear membranes to facilitate LT synthesis (130; 
131). In vivo experiments performed by Alric et al. have demonstrated that cirrhotic rats 
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treated with the calcium ionophore A23187 or opsonized zymosan induced massive LT 
secretion from macrophages. On the contrary, shortage of calcium contributed to 
reduced LT production in cirrhotic rats (132). Furthermore, in vitro study has reported 
that treatment with the calcium ionophore A23187 can increase LTB4 secretion in white 
blood cells, while the LTC4 production is similar compared to the untreated white blood 
cells isolated from the same rats. (133).  
 
Besides of interfering with LT synthesis, calcium levels can be reversely regulated 
by the LT signaling pathway. For instance, LTB4 is able to modulate calcium levels in 
human polymorphonuclear leukocytes and differentiated HL-60 cells in a 
LTB4-receptor-dependent manner (134). Moreover, LTC4 secretion can enhance the 
intracellular calcium response in the nucleus according to LTC4 doses (135). 
  
 
1.6 Reactive oxygen species 
Reactive oxygen species (ROS) such as superoxide radicals, hydrogen peroxide, 
single oxygen and hydroxyl radicals that are commonly involved in inflammatory 
reactions and pathological processes (136; 137). ROS are composed of unpaired 
electrons which are highly instable and reactive (138). Despite of being concerned as 
toxic and damaging sources in human bodies, ROS are also found pivotal in mediating 
cell signal transduction and regulating cell apoptosis (139-141). Under physiological 
conditions, ROS are produced through several intracellular events such as oxidative 
reactions carried out by NAPDH oxidases, oxidative metabolism of AA catalyzed by 
lipoxygenases, or the respiratory chain reaction conducted in mitochondria (142). Once 
produced, ROS act as specific secondary messengers in signaling cascades 
modulating cell proliferation and differentiation, through which ROS up-regulate certain 
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groups of genes related with cell growth (143).  
 
Oxidative metabolism of AA not only generates ROS as by-products during the 
oxidative reaction, but also produces unstable metabolites or intermediates that trigger 
even more ROS production by activating nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (144-147). Previous studies have revealed that fibroblasts and 
neutrophils treated with LTB4 showed increased ROS production as well as NADPH 
oxidase activation, which can mediate LTB4-induced chemotaxis (148; 149). Moreover, 
activation of CysLT1-R promotes ROS generation to regulate the pathological process 
of asthma (150). In vitro study has also proposed that ROS production increased after 
LTC4 treatment in cardiomyocytes (151). Conversely, Luchtefeld et al. found that 
inhibition of 5-LO not only abolished LTB4 formation, but also attenuated ROS 
production (152). Similarly inhibition of CysLT1-R can lower ROS generation in vessels 
to reduce atherosclerotic plaque production (151; 153). Therefore, ROS should be 
carefully taken into account when studying AA/LT metabolic pathways and the resulting 
physiological events.  
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2. Aim of the study 
Previous studies have already shown that LTs are pivotal players during the 
inflammatory response that contributes significantly to local vascular formation (154; 
155). Moreover, the inflammatory response is also accompanied by massive leukocyte 
accumulation (156). However, it remains elusive whether LTs have any influence on 
vasculogenesis or leukocyte differentiation of ES cells in response to inflammation. 
Therefore we used the ES cell line CCE S103, which is a well-established stem cell 
model, to uncover the mechanisms of how LTs participate in vasculogenesis and 
leukocyte differentiation. 
 
 
Figure 2.1 Aim of the study. 
 
To accomplish the goal of this project, we carried out experiments regarding the 
following aims (Figure 2.1): 
 
1) we investigated whether AA, the initial source of LT signaling pathway, regulates 
vasculogenesis and leukocyte differentiation.  
2) we verified the influence of FLAP, the key enhancer of LT signaling pathway, on 
vasculogenesis and leukocyte differentiation. 
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3) to further confirm the effect of LTs on vasculogenesis, we blocked the LT signaling 
pathway by FLAP inhibitors and then examined whether exogenous AA or LTs would 
restore vasculogenesis.  
4) we determined whether LT receptors play any role directly in vasculogenesis.  
5) we investigate the relationship between vasculogenesis and the AA-induced calcium 
response and ROS generation. 
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3. Materials  
3.1 Company 
Abcam Limited Cambridge CB OTP, Cambridgeshire, UK 
Abd Serotec Puchheim, Germany 
Alexis Grünberg, Germany 
AppliChem GmbH Darmstadt, Germany 
BD Biosciences GmbH Heidelberg, Germany 
Bio-Rad Laboratories, Inc. Hercules, California , USA 
Biocat  Heidelberg, Germany 
BioLegend San Diego, California, USA 
Biochrom Berlin, Germany 
Biometra Göttingen, Germany 
Biomol Lörrach, Germany 
BioVision Milpitas, California, USA 
Cell Systems Cambridge, Massachusetts, USA 
Cayman Tallinn, Estonia 
Cell Signaling Beverly, Massachusetts, USA 
Chemicon International Hampshire, UK 
Dunn Labortechnik Asbach, Germany 
Eppendorf Hamburg, Germany 
Greiner Bio-One GmbH Eberstadt, Germany 
Hanna Instruments Kehl am Rhein, Germany 
Heidolph Elektro GmbH Kehlheim, Germany 
Heraeus Instruments Hanau, Germany 
Hirschmann® Laborgeräte Eberstadt, Germany 
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IKA Staufen, Germany 
Imgenex San Diego, California, USA 
Integra Biosciences Fernwald, Germany 
Invitrogen Karlsruhe, Germany 
Kendro Laboratory Products Langenselbold, Germany 
Leica Bensheim, Germany 
Merck Darmstadt, Germany 
Merck Millipore Schwalbach/Ts., Germany 
Mettler Toledo Giessen, Germany 
Molecular Devices, LLC. Sunnyvale, California, USA 
Molecular Probes Eugene, Oregon, USA 
Oelikon Köln, Germany 
PAA Coelbe, Germany 
Panmira Pharmaceuticals, LLC.  San Diego, California, USA 
Roche Diagnostics GmbH Mannheim, Germany 
Roth Karlsruhe, Germany 
Santa Cruz Biotechnology Inc. Santa Cruz, California, USA 
Sartorius Göttingen, Germany 
Sigma – Aldrich Taufkirchen, Germany 
Thermo Erembodegem, Belgium 
Vasopharm Wuerzburg, Germany 
Whatman GmbH Dassel, Germany 
Carl Zeiss Jena, Germany 
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3.2 General materials 
5 ml polystyrene round bottom tube BD 
6 well cell culture plate Greiner 
Cell spin system Integra 
Cell strainer BD 
Confocal microscopy Leica 
Centrifuge  5417C Eppendorf  
Laborfuge 300 Heraeus  
Biofuge 15R Heraeus 
Cover slip Roth 
Eppendorf tubes Eppendorf 
Glass pipettes Roth 
Gel electrophoresis chamber Invitrogen 
Gel electrophoresis power supply Invitrogen 
Homogenizer Sigma 
Incubator HERAcell® 240 Kendro 
Laminar air hood Heraeus 
Magnetic stirrer IKA 
Microscope slides Roth 
Nitrocellulose membrane Whatman 
NuPAGE® 4-12% Bis-Tris Gel Invitrogen 
Optical microscope Carl Zeiss 
Petri perm plates Greiner 
pH-meter    Hanna Instruments 
Pipette tips Eppendorf 
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Pipettor Hirschmann/Eppendorf 
Plastic pipettes Greiner 
Reaction tubes (15 & 50 ml) Greiner 
Semi-micro balance Mettler Toledo 
Spinner flask Integra 
Tissue culture dish BD 
Vortex Heidolph 
Vacuum pump Oelikon 
Water bath Hirschmann 
 
 
3.3 Chemicals and substances 
-mercaptoethanol Sigma 
BSA Sigma 
Collagenase B Roche 
Di-sodium hydrogen phosphate dihydrate Roche 
DMEM Sigma 
DMSO Calbiochem (Merck millipore) 
Dulbecco’s PBS without Ca & Mg PAA 
EDTA Roth 
ESGRO® (LIF)   Millipore 
FCS Sigma 
Fluo-4, AM Molecular Probes 
Gelatine Cell Systems 
Glycerol Sigma 
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H2DCF-DA Molecular Probes 
Hydrogen peroxide Sigma 
IMDM Biochrom 
LDS sample buffer (4X) Invitrogen 
L-Glutamin 200 mM (100x)   PAA 
Luminol Sigma 
Methanol Merk 
Mitomycin C Sigma 
MOPS buffer Invitrogen 
NEA Biochrom 
Nonfat dried milk power AppliChem 
Nonidet P-40 AppliChem 
NuPAGE® MOPS SDS running buffer (20x) Invitrogen 
NuPAGE® sample reducing agent (10x) Invitrogen 
Novex® sharp pre-stained proteinstandard           Invitrogen 
p-Coumaric acid Sigma 
Paraformaldehyde  Roth 
Penicillin/streptomycin (100x)   PAA 
PL pro Invitrogen 
Ponceau S   AppliChem 
Potassium chloride Roth 
Potassium dihydrogen phosphate Roth 
Protease inhibitor cocktail   Biocat 
SDS Roth 
Sigmacote Sigma 
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Sodium chloride Sigma 
Sodium pyruvate (100 mM) Biochrom 
Triton X-100   Sigma 
Tris Roth 
Tris-HCl solution BioVision 
Trypsin/EDTA   Invitrogen 
Tween-20   Sigma 
VAS2870 Vasopharm 
Western blot stripping buffer Thermo 
 
 
3.4 Cell line  
CCE S103 Mouse embryonic stem cell line isolated from embryos of mouse strain 
129/sv (157). 
 
 
3.5 Medium 
Cultivation medium 
(Differentiation medium) 
Iscove’s medium (IMDM)  
15.6 % FCS  
0.1 mM -mercaptoethanol  
1 mM Sodium pyruvate 
2 mM L-Glutamin  
0.1 mM non essential amino acids (NEA)  
1 % Penicillin/Streptomycin 
EMFI medium Dulbecco’s medium (DMEM)  
2 mM L-Glutamin  
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0.1 mM NEA  
1 % Penicillin/Streptomycin 
10 % Heat-inactivated FCS 
Medium for LIF medium Iscove’s medium (IMDM)  
7.5 % FCS 
7.5 % Heat-inactivated FCS 
0.1 mM -mercaptoethanol  
2 mM Sodium pyruvate 
2 mM L-Glutamin  
0.1 mM NEA  
LIF medium Medium for LIF medium 
1000 U/ml ESGRO LIF 
5 g/ml PL pro  
 
 
3.6 Buffers 
10x PBS 1.4 M NaCl  
64.6 mM Na2KPO4 x 2H2O   
26.8 mM KCl   
14.7 mM KH2PO4          in 1L H2O  
1x PBS 100 ml 10x PBS and 900 ml H2O 
Adjust pH to 7.4 
1% PBST 100 ml 1x PBS and 1 ml Triton X-100 
0.01% PBST 100 ml 1x PBS and 100 l Triton X-100 
0.01% PBS-Tween 20 100 ml 1x PBS and 100 l Tween 20 
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10x TBS 50 mM Tris   
150 mM NaCl               in 1 L H2O  
Adjust pH to 7.54 (with HCl) 
1x TBS 100 ml 10x TBS and 900 ml H2O 
0.1% TBST 100 ml 1x TBS and 1 ml Tween 20 
RIPA-Lysis buffer 150 mM NaCl   
0.5 % Deoxycholic acid  
1 % Nonidet P-40  
0.5 % SDS  
50 mM Tris                  in H2O  
Adjust pH to 7.4 (with HCl) 
Transfer buffer 1x transfer buffer 
20% methanol 
0.1% antioxidant             in H2O 
ECL buffer 100 mM Tris-HCL (pH 8.5) 
0.225 mM p-Coumaric acid 
1.25 mM Luminol 
0.009 % (v/v) H2O2 
 
 
3.7 Antibodies 
Blocking antibody 
Purified Rat Anti-Mouse CD16/CD32 (553141) BD Pharmingen 
 
Primary antibody 
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Monoclonal rat anti-mouse CD31 (clone 390) (CBL1337) Chemicon  
Monoclonal rat anti-mouse CD144 (562243) BD Pharmingen  
Monoclonal rat anti-mouse CD18 (101409) BioLegend 
Monoclonal rabbit anti-mouse Flk-1 (#2479) Cell Signaling 
Monoclonal mouse anti-vinculin (clone hVIN-1) (V9131) Sigma 
Polyclonal goat anti-mouse PECAM-1 (sc-1506) Santa Cruz 
Biotechnology, inc. 
Polyclonal rabbit anti-mouse GAPDH (ab22555) Abcam 
Polyclonal goat anti-mouse FLAP/ALOX5AP (IMG-3160) Imgenex 
Polyclonal rabbit anti-mouse VE-Cadherin (ab33168) Abcam 
Rabbit anti-mouse -actin (13E5) (4970) Cell Signaling 
Monoclonal rat anti-mouse CD45 (05-1416) Millipore 
Monoclonal rat anti-mouse CD68 (MCA1957) Abd Serotec 
DRAQ5 (4084S) Cell Signaling 
 
Secondary antibody 
Alexa Fluor® 488 donkey anti-rat IgG (A-21208) Invitrogen 
Alexa Fluor® 488 donkey anti-rabbit IgG (A-21206) Invitrogen 
Cy5-conjugated goat anti-rat IgG (AP124S) Chemicon 
Horseradish peroxidase-conjugated horse anti-mouse IgG 
(7076S)  
Cell Signaling 
Horseradish peroxidase-conjugated goat anti-rabbit IgG 
(7074S)   
Cell Signaling 
Horseradish peroxidase-conjugated goat anti-rat IgG 
(7077S) 
Cell Signaling 
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Horseradish peroxidase-conjugated rabbit anti-goat IgG 
(AP106P)   
Millipore 
 
 
3.8 Inhibitors 
AM643 (Panmira Pharmaceuticals, LLC. AM643 was a generous gift.)   
AM643 (syn: sodium 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)- 
benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid) is a 
FLAP inhibitor that can reduce the 3H-ligand binding to FLAP membranes. Based on 
both in vitro and in vivo studies, AM643 can significantly decrease the expression of 
LTB4 and CysLTs (158). 
 
REV5901 (Biomol) 
REV5901 (syn: -Pentyl-3-(2-quinolinylmethoxy)-benzene-methanol) is a FLAP 
inhibitor, which also has dual roles as CysLT1 receptor inhibitor and a 5-LO inhibitor 
(159; 160). The compound containing a (2-quinolinylmethoxy) phenyl moiety is a highly 
specific peptidoleukotriene antagonist (161).  
 
U75302 (Cayman) 
U75302 (syn: 6-(6-(3R-hydroxy-1E, 5Z-undecadien-1-zl)-2-pyridinyl)-1,5S- 
hexanediol) is a specific antagonist for BLT1 receptor (162). 
 
LY255283 (Cayman) 
LY255283 (syn: 1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptzl]oxz] 
phenyl]-ethanone)) is a competitive antagonist for BLT2 receptor, which can also reduce 
LTB4 production (163; 164).  
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BAY-u9773 (Cayman) 
BAY-u9773 (syn: 4-[[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]-2,4,6,9- 
pentadecatetraen-1-yl]thio]-Benzoic acid) is a LTE4 analogue and a selective antagonist 
for CysLT receptors. It is the only antagonist for CysLT2-R (165). In vivo, BAY-u9773 is a 
powerful competitive inhibitor of LTC4 binding to CysLT2-R (166).  
 
BAPTA-AM (Calbiochem (Merck millipore)) 
BAPTA-AM (syn: 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
acetoxymethyl ester) is a non membrane-permeable form of BAPTA, which is a highly 
selective calcium chelator. Previous studies have showed that BAPTA-AM consumes 
vitamin D3-induced unregulated intracellular calcium. However, BAPTA-AM only binds 
the intracellular calcium and has no effect on extracellular calcium (167). 
 
VAS2870 (Vasopharm) 
VAS2870 (syn: 3-benzyl-7-(benzoxazolyl)thio-1,2,3-triazolo[4,5]pyrimidine) is a 
cell- permeable thiotriazolopyrimidine compound and a specific NADPH oxidase 
inhibitor. In vitro, VAS2870 completely prevents production of ROS and incorporation of 
thymidine (168).  
 
NMPG (Sigma) 
 NMPG (syn: N-(2-mercaptopropionyl)glycine), a diffusible antioxidant, is a 
free-radical scavenger of oxygen radicals and a reducing reagent of the oxidized form of 
Glutathione. Furthermore, NMPG can act as scavengers for vitamin C, vitamin E, 
vitamin A and coenzyme Q10 (169; 170). 
 
Trolox (Aldrich) 
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Trolox (syn: 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid) is an 
antioxidant. Trolox is a water-soluble analog of Vitamin E, which can reduce production 
of ROS and protect H2O2-induced toxicity in cells (171).  
 
 
3.9 Substances 
3.9.1 H2DCF-DA 
 H2DCF-DA (syn: 2',7'-dichlorodihydrofluorescein diacetate) is a cell-permeable 
non-polar reagent, which is used as an indicator for hydroxyl, peroxyl and other ROS 
activity. After H2DCF-DA being transferred into the cells, esterase converts H2DCF-DA 
into dichlorodihydrofluorescein (H2DCF) via cutting the acetate groups. H2DCF is 
non-cell-permeable, stays in the cells and then is oxidized to dichlorofluorescein (DCF) 
by ROS (172). Excitation wavelengths of the oxidized form are between 492-495 nm; 
fluorescence is detected at emission wavelengths of 517-527 nm. The fluorescence 
was detected by confocal laser scanning microscopy. 
 
3.9.2 Fluo-4, AM 
 Fluo-4, AM (syn: 1-[2-Amino-5-(2,7-difluoro-6-hydroxy-3-oxo-9-xanthenyl) 
phenoxy]-2-(2-amino-5-methyl-phenoxy)ethane-N,N,N’,N’-tetraacetic acid, penta- 
acetoxymethyl ester) is a common, bright and photostable indicator of intracellular 
calcium in living cells (173). Excitation is performed at 488 nm using an argon ion laser 
and emission is recorded at > 515 nm (174).  
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4. Methods 
4.1 Cell culture 
4.1.1 Mouse embryonic stem cells  
In this project, the ES cell line, CCE S103, derived from 129/Sv mouse strain was 
used (37; 157). ES cells are pluripotent cells and able to differentiate into different types 
of cells such as endothelial cells and leukocytes. To keep the ES cells undifferentiated, 
ES cells were co-cultured with confluent, mitotically inactivated feeder layers of primary 
murine fibroblasts in medium containing the cytokine LIF (30). 
 
4.1.2 Mouse embryonic fibroblasts 
To prepare mitotically inactivated feeder layers, frozen feeder cells were thawed at 
37°C in a water bath and then mixed with 20 ml warm EMFI medium. The feeder cells 
were then centrifuged at 200 g for 5 min at room temperature (RT). After centrifugation, 
the supernatant was removed and the pellet was resuspended in EMFI medium. 
Resuspended cells were plated in 5 ml EMFI medium in tissue culture plates and 
cultured for 24 h until 70% confluence. After 24 h, mitomycin C (10 g/ml) was applied 
to inactivate the feeder cells at 37°C for 3 h. Three h later, the feeder cells were washed 
with 3 ml EMFI medium for 3 times, then cultured in 5 ml fresh EMFI medium. The 
inactivated feeder layers can be only maintained for one week. Medium change with 
fresh EMFI medium should be performed everyday. 
 
4.1.3 Embryonic stem cell culture 
The ES cells were thawed in the 37°C water bath with 20 ml warm LIF medium and 
centrifuged at 200 g for 5 min. After removing the medium, ES cells were resuspended 
with the LIF medium and cultured on mitotically inactivated feeder layers (Figure 4.1). 
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The ES cells were then cultivated at 37°C, with 5% CO2 and 95% humidity. 
 
 
Figure 4.1 ES cells co-cultured with mitotically inactivated feeder layers. The scale 
bar represents 100 m. 
 
4.1.4 Passage of confluent embryonic stem cells 
Every 2 or 3 days, the ES cells were at about 70% confluence. In order to maintain 
the quality and undifferentiation of the ES cells, we passaged the cells to fresh culture 
plates containing monolayers of mitotically inactivated feeder cells. To passage the cells, 
it is mandatory to wash them once with 2 ml trypsin and then incubate cells with 2 ml 
trypsin for 30 s at 37°C.  
 
4.1.5 Differentiation of confluent embryonic stem cells 
For differentiation, the ES cells mentioned above were trypsinized. For enzymatic 
dissociation, cells were washed once with 2 ml trypsin and incubated with 2 ml trypsin 
for 30 s at 37°C. Afterwards, the reaction of trypsin was terminated by adding 6 ml 
cultivation medium. The suspended ES cells were transferred into siliconized spinner 
flasks which contained 125 ml cultivation medium (Figure 4.2). The second day, 125 ml 
cultivation medium was added to feed the cells. Starting from the next day, half of the 
medium was renewed everyday. On day 3, various substrates as indicated were applied 
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on the cells (Figure 4.3). 
 
 
Figure 4.2 Silicon-coated spinner flask for ES cell differentiation. 
 
4.1.6 Treatment conditions 
To investigate the impact of AA and LTs on EBs, the EBs were treated with AA, 
FLAP inhibitors, LTs, LT receptor inhibitors, calcium chelator or ROS antagonists from 
day 3 to day 10 of differentiation to monitor their effects on vasculogenesis. On the other 
hand, the EBs were treated with AA and FLAP inhibitors from day 3 to day 14 of 
differentiation to measure their effects on leukocyte differentiation (Table 4.1). On day 3, 
the EBs were transferred from spinner flasks to bacteriological culture plates, and the 
medium of the plates was changed everyday.  
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Figure 4.3 EBs in suspension at day 3 of cell culture. The scale bar represents 100 
m. 
 
Substance Company Concentration 
AA Sigma 100 M 
AM643 Panmira Pharmaceuticals, LLC. 5 M 
REV5901 (L-655,238) Biomol 2 M 
U75302 Cayman 1 M 
LY255283 Cayman 1 M 
BAYu9773 Cayman 1M 
LTB4 Cayman 50 nM 
LTD4 Biomol 50 nM 
12(S)-HETE Cayman 50 nM 
BAPTA-AM Calbiochem (Merck millipore) 10 M 
NMPG Sigma 100 M 
Trolox Sigma 100 M 
VAS2870 Vasopharm 50 M 
Table 4.1 Final concentration and source of substances used in the experiments. 
 
 
4.2 Immunohistochemistry 
Immunohistochemistry (IHC) is a technique to directly visualize protein localization 
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in the tissue. The protein of the cells serves as an antigen binding to the primary 
antibody, which can then be recognized by a fluorophore-conjugated secondary 
antibody. The fluorophore is able to emit fluorescence after laser excitation which can 
be detected by photo-multipliers. 
 
4.2.1 Confocal laser scanning microscopy 
 Confocal laser scanning microscopy was established based on a conventional light 
microscope, but a laser is used for the light source instead of a lamp (175). A computer 
is assembled to control and display the image scanning and collection. The laser line 
passes through a dichroic mirror to a pinhole. Fluorescence emission is recorded by 
photo multiplier tubes. The microscopy images in this thesis were taken using a Leica 
LCSM TCS-SP2 confocal laser scanning microscope equipped with the lasers: 458/488 
nm Argon, 543 nm Helium/Neon (HeNe), and 633 nm HeNe. The analyses of the 
images were carried out with Leica confoca software LCS lite (Leica) or MetaMorph 
microscopy automation and image analysis software (Molecular Devices, LLC.). 
 
4.2.2 PECAM-1 staining 
On day 10, the differentiated whole-mount EBs were collected for PECAM-1 
staining to evaluate vasculogenesis. The EBs were washed with phosphate-buffered 
saline (PBS) once and then fixed in ice-cold methanol for 20 min at -20°C. After removal 
from the methanol the EBs were washed in 0.01% PBST for 3 times. For 
permeabilization, the EBs were incubated in 1% PBST for 15 min at RT. Then EBs were 
washed with 0.01% PBST once to remove the remaining 1% PBST solution, and then 
10% milk prepared with 0.01% PBST was used for blocking unspecific binding. 
Following the 1 h blocking procedure, EBs were then incubated with primary antibody, 
monoclonal rat anti-PECAM-1 (conc. 1:100), overnight at 4°C. The next day EBs were 
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first washed with 0.01% PBST for 3 times before incubation with the secondary antibody, 
Cy5-conjugated goat anti-rat IgG (conc. 1:100), for 1 h. 1 h later, the EBs were washed 
3 times with 0.01% PBST. To quantify the vascularization, vascular structures of the EBs 
were recorded by the confocal laser scanning microscope. The images were composed 
of eight full-frame images which recorded optical slices separated by distance of 8 m in 
z-direction. The images are overlay images of the EBs. From the images, branching 
points of vascular structures were counted. The number of branching points were 
scored and divided by the cross section of the EBs (M2) for normalization.  
 
4.2.3 Leukocyte marker staining 
For leukocyte marker staining, the EBs were plated on cover slips on day 4 and 
then collected on day 14. First, the cells were washed once with PBS and incubated in 
4% paraformaldehyde (PFA) at 4°C. After 45 min of incubation, PFA was removed and 
the EBs were washed 3 times with 0.01% PBS-Tween 20, followed by blocking the EBs 
with 10% milk in PBS-Tween 20 for 1 h. Primary antibodies including monoclonal rat 
anti-mouse CD18, monoclonal rat anti-mouse CD45, and monoclonal rat anti-mouse 
CD68 (conc. 1:100) were incubated with EBs overnight at 4°C. On the next day, EBs 
were washed 3 times with 0.01% PBS-Tween 20 before application of the secondary 
antibody, Alexa Fluor® 488 donkey anti-rat IgG (conc. 1:100), for 1 h at RT in the dark. 
After 3 times washing with 0.01% PBS-Tween 20, the EBs were incubated with DRAQ5 
(conc. 1:1000) for 10 min at RT in dark for nuclear staining. Finally, the EBs were 
washed 3 times with PBS and then fixed on the slides for further use. For analyzing the 
results, the MetaMorph microscopy automation and image analysis software was used. 
The positive cells were divided by the total number of nuclei to show the percentage of 
cells positive for leukocyte markers. 
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4.3 Western blot 
4.3.1 Protein extraction 
To extract proteins, EBs were harvested in Eppendorf tubes and then washed once 
in cold PBS. Cells were homogenized with 100l complete RIPA-lysis buffer and 
incubated on ice for 20 min. Cell lysates were then centrifuged at 12,000 g for 10 min to 
obtain the supernatant, which was stored at -80 °C until further use. Protein 
concentration was accessed by Lowry assay. 
 
4.3.2 Protein gel electrophoresis 
Protein samples were separated by gel electrophoresis. The extraction protein 
samples were mixed with proportional LDS sample buffer and reducing agent at 70° C 
for 10 min before loaded on the NuPAGE® SDS-PAGE gel (Invitrogen). Electrophoresis 
was performed with NuPAGE® MOPS SDS running buffer to separate proteins by 
molecular weight. The separated proteins were then transferred to a nitrocellulose 
transfer membrane with NuPAGE® transfer buffer (1x transfer buffer, 20% methanol, 
and 0.1% antioxidant) at 200 V and 60-125 mA for 1.5 h in a transfer tank. Ponceau 
prestaining (0.5 g Ponceau S, 1 % (v/v) acetic acid and H2O) was performed to confirm 
the successful transfer.  
 
4.3.3 Antibody staining and expression 
In succession, the membranes were blocked in 5% non-fat milk in 0.1% TBST (100 
ml 1x TBS and 1 ml Tween 20) for 1 h at RT after transfer. Then, the membranes were 
probed with indicated primary antibody diluted in 5% bovine serum albumin (BSA) (in 
0.1% TBST) over night at 4°C. On the next day, the membranes were washed 3 times 
with 0.1% TBST and then incubated with corresponding secondary peroxidase-coupled 
anti-IgG antibodies diluted in 5% BSA (in 0.1% TBST) 1 h at RT. The membranes were 
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then washed 3 times with 0.1% TBST to remove the unbound secondary antibody. ECL 
buffer was used to visualize the signals from bound secondary antibodies. For analysis 
of the protein expression levels, the software ImageJ (National Institutes of Health 
(USA)) was used.  
 
 
4.4 Intracellular calcium measurement 
4.4.1 Cell dissociation and plating 
 For detecting intracellular calcium by Leica LCSM TCS-SP2 confocal laser 
scanning microscopy, EBs were enzymatically dissociated into single cells. On one day 
prior to the experiment, EBs were collected and then washed once before incubating 
with warm collagenase in PBS at 37° C for 5-10 min until EBs were dissociated into 
single cells. The isolated cells were then plated on cover slips for analysis. The 
intracellular calcium concentration was detected on day 2, day 4, day 6 and day 8 of 
differentiation. 
 
4.4.2 Intracellular calcium detection 
 On the day of intracellular calcium concentration detection, plated single cells from 
EBs were incubated for 30 min with fluo-4, AM with or without BAPTA-AM in serum-free 
medium, and then changed back to normal fresh medium. As a control, intracellular 
calcium concentration of cells was first detected with confocal laser scanning 
microscopy for the initial 100-120 s without any treatment. Subsequently EBs were 
treated with AA for detecting AA-induced changes of intracellular calcium concentration. 
The whole reaction was monitored for 1000 s. 
 
[Ca2+]=Kd[F-Fmin]/[Fmax-F] (176) 
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 Concentration of intracellular calcium was defined according to the equation above. 
F is fluorescence measured from the experiment. Kd (the dissociation constant for 
indicator) of Fluo-4, AM is 345 nM. Fmin is 2 and Fmax is 220.  
 
  
4.5 Reactive oxygen species measurement 
 ROS measurement is performed by detecting the strength of fluorescence after 
staining the EBs with the ROS fluorescence indicator H2DCF-DA. On day 4 of 
differentiation, EBs were treated with AA for 1, 2, 4, 6, and 20 h. Afterwards, the EBs 
were treated with H2DCF-DA for 30 min and then transferred into fresh medium. The 
strength of fluorescence from tested samples was detected by confocal laser scanning 
microscopy (Leica LCSM TCS-SP2) using the 488 nm line of the argon ion laser. 
Fluorescence emission was recorded at > 515 nm.  
  
 
4.6 Statistics 
All the experiments were repeated for least 3 times. The results are shown as 
mean value ± standard deviation (SD). Statistical significance was determined either by 
Student's t-test or ANOVA as appropriate. The p value of less than 0.05 was considered 
to be significant (*.#). 
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5. Results 
5.1 Effect of AA on vasculogenesis of mouse ES cells 
Previous studies have shown that vascular formation and inflammation are 
codependent events in several inflammation-related diseases (177). LTs, converted 
from AA, are inflammatory factors that can trigger the production of acute phase 
proteins to regulate the inflammatory responses (110). Additionally, previous studies 
demonstrated that the 5-LO signaling pathway can regulate vasculogenesis in ES cells 
(56). Based on these studies, we undertook to investigate whether the direct provision 
of AA for the LT signaling pathway could influence ES cell differentiation. 
 
After stimuli, the membrane-released AA is initially converted to LTA4 by 5-LO and 
the enhancer FLAP; LTA4 can either form LTB4 by the reaction catalyzed by LTA4 
hydrolase, or from CysLTs by the reaction of LTC4 synthase. Thus, we firstly 
investigated the endothelial cell markers, platelet endothelial cell adhesion molecule 
(PECAM-1) and vascular endothelial cadherin (VE-cadherin) after AA treatment to verify 
whether the ES cells differentiate to vascular cells upon AA treatment. To further confirm 
ES cell vascular differentiation, the vascular branching structures of EBs were examined 
to assess new vessels are formed.   
 
5.1.1 AA regulates the expression of PECAM-1 in a dose-dependent manner 
 To obtain the best working conditions, the first step is to optimize the working 
concentration of AA. After three days of cell culture, EBs were transferred to culture 
plates and treated from day 3 to day 10 with different concentrations of AA (50M, 100 
M, and 150M). On day 10, EBs were collected for detecting protein expression of 
PECAM-1. PECAM-1 a common endothelial cell marker is expressed in endothelial 
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intercellular junctions both in vivo and in vitro (178-181). The data showed that protein 
expression of PECAM-1 in EBs was dose-dependent increased upon treatment with 50 
M and 100 M AA (Figure 5.1). However, upon treatment of EBs with 150 M AA a 
decrease of PECAM-1 expression was observed. Based on these experiments the 
concentration of 100 M AA was selected as a suitable working concentration for further 
experiments.  
 
A) 
 
 
B)  
 
 
Figure 5.1 AA regulates the expression of PECAM-1 in a dose-dependent manner. 
Three days after differentiation, EBs were transferred to culture plates and then treated 
with AA (50M, 100M and 150M) from day 3 to day 10 of differentiation. Then, the 
EBs were collected for western blot. A) The expression of PECAM-1 after AA treatment 
increased at 50 M and 100 M, but decreased at 150 M compared with the untreated 
control. B) The bar chart showed the means ± SD of 4 independent experiments. ( *p < 
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0.05, significantly different from the untreated control). 
 
5.1.2 Influence of AA on the expression of FLAP and VE-cadherin  
 According to previous studies, FLAP plays a key role in the LT signaling pathway 
not only for transferring AA but also enhancing AA binding to 5-LO (64). Furthermore, in 
the results presented in chapter 5.1.1, we demonstrated that 50-100 M AA was able to 
increase PECAM-1 expression. However, it is still unknown whether AA can regulate the 
expression of its own metabolic pathway enhancer FLAP. To investigate the regulation 
of FLAP by AA, FLAP expression was analyzed by western blot. After 3-days of cell 
culture, EBs were transferred to culture plates and treated with 100 M AA from day 3 to 
day 10 of differentiation. On day 10, EBs were harvested for protein extraction and the 
expression of FLAP was examined. In comparison to the untreated control EBs, FLAP 
expression was significantly up-regulated after AA treatment (Figure 5.2A).  
 
To further verify whether vasculogenesis can be enhanced by AA, we also 
determined VE-cadherin expression by western blot. Comparably to PECAM-1, 
VE-cadherin is a marker for endothelial cells and is expressed in all vascular structures 
(182). As one isoform of cadherin, VE-cadherin is an endothelial-specific 
transmembrane protein functioning in cell-to-cell adherens junctions, and transfers 
intracellular signals for vascular stabilization (183). For VE-cadherin detection, ES cells 
were induced to differentiate and then transferred to culture plates and treated with 100 
M AA from day 3 to day 10. On day 10, EBs were harvested for protein extraction and 
western blot was performed for VE-cadherin detection. Compared with the untreated 
control cells, the expression of VE-cadherin was up-regulated after AA treatment (Figure 
5.2B).  
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A)                                     B) 
        
 
C) 
 
 
Figure 5.2 Influence of AA on the expression of FLAP and VE-cadherin. EBs were 
treated with AA (100 M) after differentiation induction from day 3 to day 10 of 
differentiation. Protein was collected to analyze endothelial marker and FLAP 
expression. A) The representative blot showed that the expression of FLAP was 
increased in AA-treated cells compared with the untreated control. B) The 
representative blot showed that VE-cadherin protein level was elevated in AA-treated 
cells compared with the untreated control cells. C) The bar chart showed the 
quantitative analysis of FLAP and VE-cadherin expression in relation to the 
house-keeping proteins vinculin for FLAP and -actin for VE-cadherin (n=4 in the case 
of FLAP; n=3 in the case of VE-cadherin, *p < 0.05, significantly different from the 
untreated control). 
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5.1.3 Evaluation of vasculogenesis upon AA treatment  
 During ES cell differentiation, new vessel-like structures are formed. In order to 
further confirm whether vascular structure formation can be regulated by AA, EBs were 
examined after immunohistochemical staining of endothelial cells using an antibody 
against PECAM-1. Three days after induction of cell differentiation, EBs were treated 
with AA (100M) until day 10 of differentiation and vessel-like structures were analyzed 
by confocal microscopy. The branching points in AA-treated EBs were significantly 
increased as compared with the untreated control (Figure 5.3).  
 
Taken together, these data demonstrated that AA can improve vasculogenesis of 
EBs possibly by up-regulation of the endothelial markers, PECAM-1 and VE-cadherin. 
Moreover, AA increased the level of FLAP expression thereby promoting the LT 
signaling pathway. 
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Figure 5.3 Evaluation of vasculogenesis upon AA treatment. After transfer to culture 
plates, 3-day-old EBs were treated with AA (100M) until day 10. Whole EBs were 
collected to measure branching points. The representative images showed that the 
branching points of AA-treated EBs were increased in comparison to the untreated EBs. 
The bar chart showed that the branching points of AA-treated EBs were significantly 
increased compared to the untreated control. The upper panel shows representative 
images of EBs labeled with anti PECAM-1 antibody. The scale bar represents 300 m. 
The bar chart represents mean ± SD of 3 separate experiments in which at least 30 
individual EBs were analyzed. (*p < 0.05, significantly different from the untreated 
control).  
 
 
5.2 Influence of FLAP inhibitors on vasculogenesis of mouse ES cells  
 To initiate AA conversion, FLAP is required for enhancing AA binding to 5-LO (59; 
64). Furthermore, it has been recently demonstrated that PECAM-1 expression is 
down-regulated in FLAP knockout cells (56). Therefore we assumed that FLAP might 
directly regulate ES cell differentiation due to its influences on AA conversion and 
PECAM-1 expression. Hence we evaluated the effect of FLAP on ES cell differentiation 
by blocking FLAP activity with two different FLAP inhibitors, AM643 and REV5901. 
 
The endothelial cell markers PECAM-1 and VE-cadherin were examined after 
treatment with the FLAP inhibitors AM643 and REV5901 to verify whether vascular 
differentiation of ES cells was affected. Furthermore, branching points of vascular 
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structures in EBs were measured as indicators of vasculogenesis. For this experiment, 
ES cells were induced for differentiation and then treated with either AM643 (5 M) or 
REV5901 (2 M), respectively, from day 3 to day 10 of differentiation. Whole EBs were 
analyzed for vasculogenesis by IHC while the extracted proteins of EBs were subjected 
to western blot for analysis of PECAM-1 and VE-cadherin expression. 
  
5.2.1 Evaluation of FLAP expression upon FLAP inhibitor treatment 
 To confirm the function of the FLAP inhibitors AM643 and REV5901, we examined 
FLAP expression by western blot after AM643 and REV5901 treatment. The western 
blot results revealed that FLAP expression was down-regulated by both inhibitors, 
AM643 and REV5901, as compared with the untreated control cells (Figure 5.4).  
 
A)                                        B) 
                
 
C) 
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Figure 5.4 Evaluation of FLAP expression upon FLAP inhibitor treatment. EBs 
were treated form day 3 until day 10 with the FLAP inhibitors, AM643 (5 M) and 
REV5901 (2 M), respectively. Proteins were collected and detected on day 10. The 
representative pictures of western blots showed that expression of FLAP was 
decreased after A) AM643 and B) REV5901 treatment compared with the untreated 
control cells. C) The quantification results of the western blots showed the statistically 
significant decrease of FLAP expression in the cells treated with AM643 or REV5901 
compared to the untreated control. Each value represents the mean ± SD of 3 separate 
experiments. *p < 0.05, significantly different from the untreated control. 
 
5.2.2 Effect of FLAP inhibitors on the expression of PECAM-1 and VE-cadherin  
 After confirming the efficacy of FLAP inhibitors on FLAP expression, the level of 
vasculogenesis in response to treatment with AM643 and REV5901 was investigated. 
After induction for differentiation for 3 days, EBs were transferred into culture plates and 
treated with either AM643 (5 M) or REV5901 (2 M) until day 10. On day 10, proteins 
were collected and the levels of the vascular markers PECAM-1 and VE-cadherin were 
examined by western blot. The results showed that PECAM-1 and VE-cadherin were 
both down-regulated following treatment with AM643 and REV5901, respectively 
(Figure 5.5).  
 
A)                                        B) 
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C) 
 
 
D)                                       E) 
         
 
F) 
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Figure 5.5 Effect of FLAP inhibitors on the expression of PECAM-1 and 
VE-cadherin. After differentiation for 3 days, EBs were treated with either AM643 (5 M) 
or REV5901 (2 M) until day 10. A) The representative blot showed that PECAM-1 
expression of EBs treated with AM643 (5 M) decreased compared with the untreated 
control cells. B) The representative blot showed similar reduction of PECAM-1 
expression in EBs treated with REV5901 (2 M) in comparison to the untreated control 
cells. C) The bar charts corresponding to western blots presented the down-regulation 
of PECAM-1 expression in the cells treated with either AM643 or REV5901 compared to 
the untreated control. (n=3 in the case of AM643; n=4 in the case of REV5901, *p < 0.05, 
significantly different to the untreated control) D) The representative blot revealed that 
VE-cadherin expression of EBs treated with AM643 (5 M) was reduced compared to 
untreated control EBs. E) The representative blot showed similar reduction of 
VE-cadherin expression in EBs that were treated with REV5901 (2 M) compared to the 
untreated control cells. F) The bar charts corresponding to western blots demonstrated 
significant reduction of VE-cadherin expression in the cells treated with either AM643 or 
REV5901 compared to the untreated control (n=4 in the case of AM643; n=3 in the case 
of REV5901, *p < 0.05, significantly different to the untreated control). 
 
5.2.3 Impact of FLAP inhibitors on vasculogenesis 
 To further confirm the impact of FLAP inhibitors AM643 and REV5901 on 
vasculogenesis, we examined branching points of PECAM-1 positive vascular 
structures in whole EBs using IHC. From day 3 of differentiation, EBs were treated with 
either AM643 (5M) or REV5901 (2M) until day 10 and subjected to IHC for 
PECAM-1. The results indicated that branching points of vascular structures in EBs 
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were decreased following FLAP inhibition compared to the untreated control cells 
(Figure 5.6). Taken together, the results in 5.2 suggest that inhibition of FLAP 
expression attenuates vasculogenesis by down-regulating the protein expression of 
PECAM-1 and VE-cadherin and decreasing vascular structure formation. 
 
Aa) 
 
 
Ab) 
 
 
B) 
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Figure 5.6 Impact of FLAP inhibitors on vasculogenesis. For detecting 
vasculogenesis of the EBs, they were treated with either AM643 (5 M) or REV5901 (2 
M) from day 3 to day 10 of differentiation. Branching points were examined in whole 
EBs on day 10. A) Treatment of EBs with either AM643 or REV5901 (Ab) reduced 
vascular differentiation compared to the untreated control (Aa). B) The bar charts 
showed that the branching points of EBs treated with FLAP inhibitors were significantly 
decreased compared with the untreated control EBs. The upper panel shows 
representative images of EBs labeled with anti-PECAM-1 antibody. The scale bar 
represents 300 m. The bar chart represents means ± SD of 3 separate experiments in 
which at least 30 individual EBs were analyzed. *p < 0.05, significantly different from the 
untreated control. 
 
 
5.3 AA regulated vasculogenesis of mouse ES cells is FLAP-dependent 
 The results 5.1 and 5.2 showed that AA (result 5.1) and FLAP (result 5.2) play roles 
in regulating vasculogenesis. However, AA transforming enhancer FLAP only involves in 
one of the possible AA metabolic pathways (184; 185). Therefore, we investigated 
whether FLAP is essential for AA-induced vasculogenesis. To achieve this aim 
3-day-old EBs were treated with the FLAP inhibitors AM643 (5 M) or REV5901 (2 M) 
and AA (100 M) individually, or first pre-treated with FLAP inhibitors AM643 (5 M) or 
REV5901 (2 M) for 1 h and then followed by treatment with AA (100 M) until day 10. 
On day 10, whole EBs were harvested to examine vasculogenesis by IHC. The results 
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showed that branching points of FLAP inhibitor-treated cells were decreased while 
vasculogenensis of AA-treated cells was increased compared to the untreated control 
EBs (Figure 5.7A). As expected, pre-treatment with FLAP inhibitors AM643 or REV5901 
before AA application significantly reduced vasculogenesis of EBs in comparison with 
AA-treated EBs (Figure 5.7A and 5.7B). These results indicate that AA requires 
FLAP-dependent metabolic pathways for mediating vasculogenesis.  
 
Aa) 
 
 
 
Ab) 
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B) 
 
 
Figure 5.7 AA regulated vasculogenesis of mouse ES cells is FLAP-dependent. 
3-day-old EBs were treated either with FLAP inhibitors AM643 (5 M) or REV5901 (2 
M) or AA (100 M) individually, or were pre-treated first with FLAP inhibitors before AA 
application from day 3 until day 10 of differentiation. EBs were collected on day 10 for 
analysis of branching points by IHC. The IHC shown in A images showed that both 
FLAP inhibitors reduced vasculogenesis while AA up-regulated vasculogenesis 
compared to the untreated control. EBs pre-treated with both FLAP inhibitors, AM643 
and REV5901, before AA treatment showed significantly decreased branching points as 
compared to EBs treated with AA alone. B) The bar chart showed the effects of AA, 
AM643 and REV5901 on vasculogenesis of ES cells. The upper panel shows 
representative images of EBs labeled with anti PECAM-1 antibody. The scale bar 
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represents 300 m. The bar chart represents mean ± SD of 3 separate experiments in 
which at least 30 individual EBs were analyzed. *p < 0.05, significantly different from the 
untreated control group. #p < 0.05, significantly different from the AA-treated group. 
 
 
5.4 Effect of exogenous LTs on vasculogenesis of mouse ES cells upon FLAP 
inhibition 
 Our data showed that AA-regulated vasculogenesis is dependent on 
FLAP-dependent metabolic signaling (see 5.3). Additionally, BLT1 and BLT2 have been 
found to regulate endothelial cell proliferation, differentiation and migration (57). Hence, 
we speculated that LTs, the AA derivatives from FLAP, may involve in vasculogenesis. 
To verify our hypothesis, EBs were co-treated with FLAP inhibitors i.e. AM643 and 
REV5901, and LTs including LTB4, LTD4 and a ligand of BLT1 and BLT2, 
12S-hydroxy-5Z, 8Z, 10E, 14Z- eicosatetraenoic acid (12(S)-HETE), from day 3 to day 
10 of differentiation (57). On each day, EBs were pre-treated with AM643 (5M) or 
REV5901 (2M) for 1 h before treatment with LTB4 (50 nM), LTD4 (50 nM), and 
12(S)-HETE (50 nM), respectively. The effect of LTs on vasculogenesis was determined 
by protein expression of the endothelial markers PECAM-1 and VE-cadherin expression 
as well as branching points of vascular structures. 
 
5.4.1 Exogenous LTB4 restores the decrease of PECAM-1 and VE-cadherin 
expression upon treatment with FLAP inhibitors  
 In order to investigate whether LTB4 regulates vasculogenesis, we inhibited FLAP 
using AM643 and REV5901 either in the absence or presence of exogenous LTB4 and 
assessed protein expression of PECAM-1 and VE-cadherin. Western blot experiments 
on day 10 of differentiation demonstrated that PECAM-1 expression of AM643- (5 M) 
-and REV5901-(2 M) treated EBs was down-regulated compared to the untreated 
control. PECAM-1 expression of EBs treated with LTB4 (50 nM) was slightly increased in 
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comparison to the untreated control cells. Remarkably exogenous addition of LTB4 (50 
nM) significantly reversed the down-regulation of PECAM-1 expression observed upon 
pretreatment with AM643 or REV5901 (Figure 5.8A and 5.8B). Likewise the 
down-regulation of VE-cadherin expression of EBs upon pre-treatment with FLAP 
inhibitors was restored compared to EBs that were treated with inhibitors alone (Figure 
5.8C and 5.8D).   
 
A)                                      B) 
        
 
     
 
C)                                     D) 
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Figure 5.8 Exogenous LTB4 restores the decrease of PECAM-1 and VE-cadherin 
expression upon treatment with FLAP inhibitors. 3-day-old EBs were treated either 
with the FLAP inhibitors AM643 (5 M) or REV5901 (2M) either in the absence or 
presence of exogenous LTB4 (50 nM). On day 10, these EBs were harvested for 
analysis by western blot. A,B) The representative blots showed that PECAM-1 
expression was decreased after AM643 or REV5901 treatment compared to the 
untreated control cells. The treatment of LTB4 did not significantly change PECAM-1 
expression in comparison to the untreated control EBs. The decrease in PECAM-1 
expression upon FLAP inhibitor treatment was reversed upon treatment with exogenous 
LTB4 as compared to EBs treated with FLAP inhibitors alone. The bar charts 
corresponding to western blots demonstrated that the significant reduction of PECAM-1 
expression after the treatment with either AM643 or REV5901 was reversed upon 
treatment with exogenous LTB4 compared to the untreated control (n=4). C,D) Similar 
results were observed for VE-cadherin expression under same treatment conditions. 
The bar charts corresponding to western blots demonstrated that the significant 
reduction of VE-cadherin expression after treatment with either AM643 or REV5901 
was reversed upon treatment with exogenous LTB4 compared to the untreated control 
(n=4 in the case of AM643; n=3 in the case of REV5901). *p < 0.05 compared to the 
untreated control. #p < 0.05 compared to FLAP inhibitor-treated alone cells. 
 
5.4.2 Exogenous 12(S)-HETE restores the decrease of PECAM-1 and VE-cadherin 
expression upon treatment with FLAP inhibitors 
Next, we investigated whether 12(S)-HETE, a ligand of BLT1 and BLT2, has the 
same ability as LTB4 to restore vasculogenesis after FLAP inhibitor treatment. The 
expression of the endothelial markers PECAM-1 and VE-cadherin in EBs was analyzed 
by western blot. Western blot experiments of 10-day-old differentiated cells revealed 
 59 
that the expression of PECAM-1 in AM643-(5 M) and REV5901-(2 M) treated EBs 
was down-regulated compared to the untreated control cells. PECAM-1 expression of 
EBs treated with 12(S)-HETE (50 nM) was comparable to the untreated control. The 
PECAM-1 expression of EBs pre-treated with FLAP inhibitors and subsequently with 
12(S)-HETE was restored - yet without statistical significance -as compared to FLAP 
inhibitor-treated EBs (Figure 5.9A and B). VE-cadherin expression of co-treated EBs 
was also restored - yet without statistical significance - compared to FLAP 
inhibitor-treated EBs (Figure 5.9C and 5.9D).  
 
A)                                       B) 
     
 
     
  
C)                                         D) 
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Figure 5.9 Exogenous 12(S)-HETE restores the decrease of PECAM-1 and 
VE-cadherin expression upon treatment with FLAP inhibitors. 3-day-old EBs were 
treated from day 3 until day 10 of differentiation with the FLAP inhibitors, AM643 (5 M) 
or REV5901 (2 M) either in the presence or absence of 12(S)-HETE (50 nM). On day 
10, proteins were extracted and the expression of PECAM-1 and VE-cadherin was 
examined by western blot. A,B) Representative blots showed that PECAM-1 expression 
of EBs treated with AM643 or REV5901 was decreased compared to the untreated 
control. 12(S)-HETE alone had no effect on PECAM-1 expression in EBs compared to 
the untreated control. Upon pre-treatment with AM643 and then 12(S)-HETE the 
down-regulation of PECAM-1 expression was partially reserved in comparison to 
AM643- and REV5901-treated EBs. The bar charts corresponding to western blots 
demonstrated that the reduction of PECAM-1 expression was only partially reversed 
upon 12(S)-HETE treatment (n=4). C,D) Similar results were observed for VE-cadherin 
expression under the same treatment conditions. The bar charts corresponding to 
western blots suggested that the reduction of VE-cadherin expression was only partially 
reversed upon 12(S)-HETE treatment (n=3). *p < 0.05 compared to the untreated 
control. #p < 0.05 compared to FLAP inhibitor-treated cells.) 
 
5.4.3 Exogenous LTD4 restores the decrease of PECAM-1 and VE-cadherin 
expression upon treatment with FLAP inhibitors 
Besides LTB4, CysLTs are also FLAP-dependent AA metabolites. Therefore, we 
postulated that CysLTs might participate in FLAP-mediated vasculogenesis. To 
investigate whether CysLT-LTD4 can restore the inhibition of vasculogenesis upon 
treatment with FLAP inhibitors, the expression of PECAM-1 and VE-cadherin in EBs 
was examined after exogenous addition of LTD4. As shown in the representative blot, 
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PECAM-1 expression in AM643-(5 M) and REV5901-(2 M) treated EBs was 
decreased compared to the untreated control cells (Figure 5.10A and 5.10B). The 
expression of PECAM-1 in EBs treated with LTD4 (50 nM) alone was comparable to the 
untreated control cells. The expression of PECAM-1 was restored in EBs co-treated 
with LTD4 after AM643 pre-treatment compared to cells treated with AM643 alone 
(Figure 5.10A). However, LTD4 did not significantly restore PECAM-1 expression in EBs 
pre-treated with REV5901 (Figure 5.10B). VE-cadherin expression of EBs pre-treated 
with AM643 first and then LTD4 was also restored in comparison to the untreated 
controls (Figure 5.10C and D).  
 
A)                                      B) 
    
 
     
 
C)                                       D) 
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Figure 5.10 Exogenous LTD4 restores the decrease of PECAM-1 and VE-cadherin 
expression upon treatment with FLAP inhibitors. 3-day-old EBs were treated with 
FLAP inhibitors (AM643 (5 M) or REV5901 (2 M)), LTD4 (50 nM) or FLAP inhibitors 
together with LTD4 until day 10, and proteins were harvested for western blot analysis. 
A,B) The expression of PECAM-1 in EBs treated with AM643 or REV5901 was 
decreased compared to the untreated controls. PECAM-1 expression in EBs treated 
with LTD4 was comparable to the untreated control cells. Addition of LTD4 (50 nM) 
reversed PECAM-1 expression of EBs pre-treated with 5 M AM643 in comparison to 
EBs treated with AM643 alone. However, LTD4 did not significantly reverse the 
down-regulated PECAM-1 expression in EBs pre-treated with REV5901 alone. The bar 
charts corresponding to western blots demonstrated significant reduction of PECAM-1 
expression after the treatment with AM643 which was reversed upon treatment with 
exogenous LTD4. This was not the case in EBs pre-treated with REV5901 and then 
LTD4 (n=3). C,D) Similar results were observed for VE-cadherin expression under the 
same treatment conditions. The bar charts corresponding to western blots suggested 
that the significant reduction of VE-cadherin expression after treatment with AM643 was 
reversed upon co-administration of exogenous LTD4. VE-cadherin expression of EBs 
pre-treated with REV5901 and then LTD4 was not restored compared to the untreated 
control (n=3). *p < 0.05, significantly different from the untreated control. #p < 0.05, 
significantly different from FLAP inhibitor-treated cells. 
 
5.4.4 Effects of LTs on vasculogenesis upon treatment with FLAP inhibitors 
To further confirm the physiological effects of LT supplementation on EBs treated 
with FLAP inhibitors, branching points were measured as indicators for vasculogenesis. 
As shown in figure 5.11A, branching points of EBs treated with the FLAP inhibitors, 
AM643 (5 M) or REV5901 (2 M), were decreased compared to the untreated controls 
(Figure 5.11A). In contrast, EBs treated with LTB4 (50 nM), LTD4 (50 nM) or 12(S)-HETE 
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(50 nM) showed no differences in the numbers of branching points compared to the 
untreated control EBs (Figure 5.11A). Interestingly, we found that additional supplement 
of some LTs restored the branching points attenuated by FLAP inhibitors. LTB4 restored 
the branching points reduced by either AM643 or REV5901 in EBs while LTD4 only 
recovered the branching points upon treatment with AM643 but not with REV5901 
(Figure 5.11B). In the case of 12(S)-HETE, the branching points were partially restored 
following co-treatment with FLAP inhibitors and 12(S)-HETE. These data suggest that 
vasculogenesis reduced by FLAP inhibitors can be restored upon exogenous addition of 
LTB4 and 12(S)-HETE although the results of 12(S)-HETE did not reach statistical 
significance. The supplement of LTD4 only restored AM643-inhibited vasculogenesis 
(Figure 5.11C). All together, the results from 5.4.1 to 5.4.4 provide evidence that LTB4, 
LTD4, and 12(S)-HETE participate in the LT signaling pathway to regulate 
vasculogenesis. 
 
Aa)  
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Ad) 
 
 
B)  
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D) 
 
 
Figure 5.11 Effects of LTs on vasculogenesis upon treatment with FLAP inhibitors. 
From day 3 until day 10 of differentiation EBs were treated with the FLAP inhibitors 
AM643 (5 M) or REV5901 (2 M), or LTs (LTB4 (50 nM), LTD4 (50 nM), or 12(S)-HETE 
(50 nM)), or the combination of both, respectively. Aa) The representative pictures 
showed decreased branching points in FLAP inhibitor-treated EBs compared to the 
untreated control EBs. The LT-treated EBs showed nearly the same amount of 
branching points as the untreated EBs. Ab) The representative pictures suggested that 
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EBs, which were pre-treated with FLAP inhibitors, contained increased branching points 
after LTB4 supplement compared to EBs treated with FLAP inhibitors alone. Ac) Addition 
of 12(S)-HETE partially restored the number of branching points reduced by both FLAP 
inhibitors. Ad) Compared to EBs treated with FLAP inhibitors alone, addition of LTD4 
increased the number of branching points in EBs pre-treated with AM643 but not with 
REV5901. B-D) The bar charts showed the effect of LTB4 (B), 12(S)-HETE (C) and LTD4 
(D) on branching points (%) in either presence or absence of AM643 and REV5901. The 
upper panel shows representative images of EBs labeled with anti PECAM-1 antibody. 
The scale bar represents 300 m. The bar chart represents mean ± SD of 3 separate 
experiments in which at least 30 individual EBs were analyzed. *p < 0.05 compared to 
the untreated control cells. #p < 0.05 compared to FLAP inhibitor-treated cells. 
 
 
5.5 Influence of the LTB4 signaling pathway on vasculogenesis 
 In result 5.4.1 we realized that LTB4 is one of the mediators of AA-induced 
FLAP-dependent vasculogenesis. To further investigate how the LTB4 signaling pathway 
involves in vascular differentiation, we inhibited BLT1 or BLT2 with either U75302 which 
is a specific inhibitor for BLT1 or LY255283 which is a BLT2 inhibitor. EBs were treated 
with U75302 (1 M) or LY255283 (1 M), respectively, from day 3 to day 10 of 
differentiation and then subjected to vasculogenesis examination. Branching points and 
expression of endothelial markers including PECAM-1, VE-cadherin and Flk-1 were 
assessed as indicators of vasculogenesis.  
 
5.5.1 Impact of LTB4 receptors for the expression of PECAM-1, VE-cadherin and 
Flk-1 
 After treatment of EBs with either U75302 (1 M) or LY255283 (1 M) from day 3 to 
day 10 of differentiation, EBs were collected for detecting the expression of the 
endothelial markers PECAM-1, VE-cadherin and Flk-1. Our data showed significant 
reduction of PECAM-1, VE-cadherin and Flk-1 expression in EBs treated with BLT1 and 
BLT2 antagonists in comparison to the untreated control cells (Figure 5.12). 
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A) 
 
 
 
 
B) 
 
 
 
 
C) 
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Figure 5.12 Impact of LTB4 receptors for the expression of PECAM-1, VE-cadherin 
and Flk-1. EBs were treated with BLT1/2 receptor inhibitors (U75302 (1 M) or 
LY255283 (1 M)) from day 3 to day 10 of differentiation and collected on day 10. A) 
The representative pictures and bar charts showed that PECAM-1 expression was 
decreased in BLT1/2 inhibitor-treated EBs compared to the untreated control cells (n = 
4). B) Expression of VE-cadherin in EBs treated with U75302 and LY255283 was also 
decreased in comparison to the untreated control cells both presented in the 
representative pictures and bar charts (n = 4). C) Likewise representative pictures and 
statistic analysis of Flk-1 expression showed reduction in BLT1/2 inhibitor-treated EBs 
compared to the untreated controls (n = 3) *p < 0.05, significantly different from the 
untreated control. 
 
5.5.2 Effect of LTB4 receptor inhibition on vascular structures 
Analysis of PECAM-1 positive branching points was further used to confirm the 
effects of BLT1/2 inhibitor treatment on vascular structure formation. The experimental 
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protocols were the same as described in 5.5.1. In comparison to the untreated control 
cells, the number of branching points in EBs treated with U75302 (1 M) or LY255283 (1 
M) were significantly decreased (Figure 5.13). The statistical analysis of the number of 
branching points in EBs treated with U75302 or LY255283 also showed significant 
reduction of vascular structures compared to the untreated control cells. Taken together, 
these data suggested that LTB4 involves in LT signaling pathway-regulated 
vasculogenesis via binding to its receptor BLT1/2.  
 
Aa) 
 
 
Ab) 
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Figure 5.13 Effect of LTB4 receptor inhibition on vascular structures. EBs were 
treated with either U75302 (1 M) or LY255283 (1 M) from day 3 to day 10 of 
differentiation. On day 10, EBs were collected and the branching points of EBs were 
examined. A) The representative pictures showed that EBs treated with U75302 and 
LY255283 contained reduced numbers of branching points in comparison to the 
untreated control cells. B) The quantified results also demonstrated that branching 
points of EBs treated with BLT1/2 inhibitors were significantly down-regulated in 
comparison to the untreated control. The upper panel shows representative images of 
EBs labeled with anti PECAM-1 antibody. The scale bar represents 300 m. The bar 
chart represents mean ± SD of 3 separate experiments in which at least 30 individual 
EBs were analyzed (n = 4 in the case of LY255283; n = 5 in the case of U75302). *p < 
0.05, significantly different from the untreated control. 
 
 
5.6 Impact of the CysLT inhibitor BAYu9773 on vasculogenesis of mouse ES 
cells 
 Based on the result shown in 5.4.3, LTD4, which is the metabolite of AA and a part 
of the CysLT signaling pathway, is involved in the signaling pathway of AA-induced 
vasculogenesis. Furthermore, we found in result 5.5 that LTB4, another metabolite of AA 
signaling pathway, involves in vasculogenesis. Therefore, we postulated that LTD4 
might regulate vasculogenesis via the CysLT receptor. To validate this hypothesis, the 
CysLT receptor inhibitor, BAYu9773, was used. EBs were treated with BAYu9773 (1 M) 
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from day 3 to day 10 of differentiation and then collected on day 10. The expression of 
PECAM-1, VE-cadherin and Flk-1 and branching points of EBs were assessed.  
 
5.6.1 Effect of BAYu9773 on the expression of PECAM-1, VE-cadherin and Flk-1 
The expression of the endothelial markers PECAM-1, VE-cadherin and Flk-1 was 
examined after BAYu9773 treatment. EBs were treated from day 3 till day 10 of 
differentiation, with BAYu9773 (1 M) and then collected on day 10 for western blot 
analysis. The expression of all three endothelial markers, PECAM-1, VE-cadherin and 
Flk-1 was down-regulated in EBs treated with BAYu9773 in comparison to the untreated 
controls (Figure 5.14).  
 
A) 
     
 
B) 
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C)  
     
 
Figure 5.14 Effect of BAYu9773 on the expression of PECAM-1, VE-cadherin and 
Flk-1. EBs were collected after treatment with or without BAYu9773 (1 M) from day 3 
to day 10 of differentiation and then protein expression of endothelial markers was 
detected. As shown in blots and bar charts, (A) PECAM-1, (B) VE-cadherin, and (C) 
Flk-1 expression were all reduced after BAYu9773 treatment compared to the untreated 
control cells (n = 4 in the case of PECAM-1 and VE-cadherin, n = 3 in the case of Flk-1). 
*p < 0.05, significantly different from the untreated control. 
 
5.6.2 Effect of the CysLT receptor inhibitor BAYu9773 on the formation of vascular 
structures  
 To further confirm the effects of BAYu9773 treatment on vasculogenesis, PECAM-1 
positive branching points were examined. The branching points in BAYu9773-treated 
EBs were significantly decreased compared to the untreated control (Figure 5.15). 
Taken together, the data from result 5.6 suggest that CysLTs take part in LT signaling 
pathway-regulated vasculogenesis through binding to the corresponding receptor. 
 
A) 
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B) 
 
 
Figure 5.15 Effect of the CysLT receptor inhibitor BAYu9773 on the formation of 
vascular structures. From day 3 to day 10 of differentiation, EBs were treated with the 
CysLTs receptor inhibitor BAYu9773 (1M), and then collected on day 10 for whole EB 
staining to analyze PECAM-1 positive branching points. A) The EBs treated with 
BAYu9773 displayed reduced vascular differentiation in comparison to the untreated 
control EBs. B) Bar charts demonstrated that the branching point numbers of EBs 
treated with BAYu9773 were significantly decreased compared to the untreated control 
EBs. The scale bar represents 300 m. The bar chart represents mean ± SD of 3 
separate experiments in which at least 30 individual EBs were analyzed. *p < 0.05, 
significantly different from the untreated control. 
 
 
5.7 Influence of combined LTB4 and CysLT receptor inhibitors on 
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vasculogenesis of mouse ES cells 
Based on result 5.5 and 5.6, LTB4 and CysLTs involve in FLAP-dependent 
vasculogenesis; however, each of them seems to participate only partially in this 
signaling pathway. To delineate the effect of the entire LT signaling pathway on 
vasculogenesis more precisely, three different LT receptor inhibitors, U75302, 
LY255283, and BAYu9773, were used together to examine the influence of overall 
blocking of the LT signaling pathway on vasculogenesis. Differentiated EBs were treated 
with or without the combination of three inhibitors, U75302 (1 M), LY255283 (1 M) 
and BAYu9773 (1 M) from day 3 to day 10 of differentiation. EBs were then collected to 
measure branching points of vascular structures and PECAM-1, VE-cadherin and Flk-1 
expression.  
 
5.7.1 Effect of combined treatment of EBs with LTB4 and CysLTs receptor 
inhibitors on PECAM-1, VE-cadherin and Flk-1 expression 
To verify the occurrence of vasculogenesis, the expression of endothelial cell 
markers i.e. PECAM-1, VE-cadherin and Flk-1 were examined after combined treatment 
with the inhibitors U75302, LY255283 and BAYu9773. From day 3 to day 10 of 
differentiation, EBs were treated with or without combined inhibitors (U75302 (1 M), 
LY255283 (1 M), and BAYu9773 (1 M)). A significant reduction in PECAM-1 
expression was observed in EBs treated with combined inhibitors U75302, LY255283, 
and BAYu9773 (Figure 5.16A); similarly, the VE-cadherin expression was 
down-regulated in treated EBs (Figure 5.16B) compared to the untreated control cells. 
In parallel, Flk-1 expression was significantly decreased in EBs treated with combined 
inhibitors in comparison to the untreated EBs (Figure 5.16C). 
 
A) 
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B) 
     
 
C) 
     
 
Figure 5.16 Effect of combined treatment of EBs with LTB4 and CysLTs receptor 
inhibitors on PECAM-1, VE-cadherin and Flk-1 expression. To measure the 
expression of endothelial markers, EBs were collected on day 10 after treatment for 7 
days with or without LTB4 and CysLT receptor inhibitors (U75302 (1 M), LY255283 (1 
M), and BAYu9773 (1 M)). The representative images and bar charts showed that the 
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expression of (A) PECAM-1, (B) VE-cadherin, and (C) Flk-1 were decreased in treated 
EBs compared to the untreated control cells (Com = inhibitor combination of U75302, 
LY255283, and BAYu9773). Each value represents the mean ± SD of 3 separate 
experiments. *p < 0.05 compared to the untreated control. 
 
5.7.2 Effect of combined treatment of EBs with LTB4 and CysLTs receptor 
inhibitors on vasculogenesis  
Vasculogenesis of EBs treated with LTB4 and CysLT receptor inhibitors was 
significant decreased as indicated by the reduction of branching points compared to the 
untreated control cells (Figure 5.17). Taken together, the result of 5.7 suggested that 
combined inhibition of LTB4 and CysLTs receptors exerted a stronger inhibition of 
vasculogenesis as compared to selective inhibition of either the LTB4 or the CysLT 
signaling pathway. 
 
A) 
 
 
B) 
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Figure 5.17 Effect of combined treatment of EBs with LTB4 and CysLTs receptor 
inhibitors on vasculogenesis. From day 3 to day 10 of differentiation, differentiated 
EBs were treated with or without the LTB4 and the CysLT receptor inhibitors U75302 (1 
M), LY255283 (1 M), and BAYu9773 (1 M), and were then collected on day 10 for 
experiments. A) Compared to the untreated control, branching points of EBs treated 
with combination of inhibitors was decreased. B) The bar charts showed the 
significance of vasculogenesis reduction in the LTB4 and the CysLT receptor 
inhibitor-treated EBs in comparison to the untreated control (Com = inhibitor 
combination of U75302, LY255283, and BAYu9773). The upper panel shows 
representative images of EBs labeled with anti PECAM-1 antibody. The scale bar 
represents 300 m. The bar chart represents mean ± SD of 3 separate experiments in 
which at least 30 individual EBs were analyzed. *p < 0.05 compared to the untreated 
control. 
 
 
5.8 Effect of AA on leukocyte differentiation of mouse ES cells 
 Previous studies have shown that inflammatory responses, in which LTs are key 
mediators, not only contribute to vasculogenesis but also promote leukocyte 
accumulation (186). In result 5.1 we have proved that AA can enhance vasculogenesis 
in EBs. Interestingly, evidences have indicated that endothelial cells and leukocytes 
originally arise from the same progenitor cells (187; 188). Therefore we postulated that 
AA treatment might also influence leukocyte differentiation. For analyzing whether AA 
regulates leukocyte differentiation, EBs were plated on cover slips on day 4 after 
differentiation induction and collected on day 14. Treatment of EBs with AA (100 M) 
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was performed from day 3 until day 14. Two common leukocyte markers, CD18 and 
CD45 and the macrophage marker CD68 were used to examine leukocyte 
differentiation (189-191). Leukocyte differentiation was significantly up-regulated after 
AA treatment in comparison to the untreated control cells as indicated by increased 
numbers of cells expressing leukocyte cell markers (Figure 5.18). Taken together, AA 
not only increased vasculogenesis but also enhanced leukocyte differentiation. 
 
A) 
 
 
B) 
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Figure 5.18 Effect of AA on leukocyte differentiation of mouse ES cells. After 
differentiation induction, 4-day-old EBs were plated on cover slips and treated with AA 
(100 M) from day 3 to day 14 of differentiation. The plated-EBs were collected on day 
14 for leukocyte differentiation detection. A) The representative images showed that the 
number of cells positive for the leukocyte cell markers CD18, CD45, and CD68 in 
AA-treated EBs was increased compared to the untreated control (n = 3 in the case of 
CD18 and CD45, n = 4 in the case of CD68). B) The bar charts indicated that leukocyte 
differentiation of EBs treated with AA was significantly enhanced compared to the 
untreated control. *p < 0.05 compared to the untreated control. The scale bar represents 
20 m. 
 
 
5.9 Impact of FLAP inhibitors on leukocyte differentiation of mouse ES 
cells 
According to the result 5.2, 5.3 and 5.8, FLAP inhibitors down-regulated 
vasculogenesis while LT signaling pathways participated in leukocyte differentiation. 
Therefore, we aimed to address whether the FLAP inhibitors AM643 and REV5901 
would down-regulate leukocyte differentiation in addition to attenuate vasculogenesis. 
We treated EBs with the FLAP inhibitors AM643 (5 M) and REV5901 (2 M) from day 3 
to day 14 of differentiation. 4-day-old differentiated EBs were plated on cover slips and 
were then collected on day 14. The leukocyte and macrophage markers CD18, CD45 
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and CD68 were examined. Our results showed that FLAP inhibitors AM643 and 
REV5901 down-regulated leukocyte differentiation compared to the untreated control 
(Figure 5.19). Based on result 5.2 and 5.9, FLAP inhibitors interfered not only with 
leukocyte differentiation but also with vasculogenesis. 
 
A) 
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Figure 5.19 Impact of FLAP inhibitors on leukocyte differentiation of mouse ES 
cells. EBs were treated with the FLAP inhibitors AM643 (5 M) or REV5901 (2 M) from 
day 3 to day 14 and plated on cover slips from day 4 to day 14 of differentiation. EBs 
were then harvested to measure the expression of CD18, CD45, and CD68. A) The 
representative images showed that the number of cells positive for the cell markers 
CD18, CD45, and CD68 were decreased after treatment of EBs with AM643 and 
REV5901 compared to the untreated control. B) The bar charts and statistic results 
showed that EBs treated with AM643 or REV5901 contained significantly decreased 
numbers of CD18, CD45, and CD68-positive cells in comparison to the untreated 
control (n = 4). *p < 0.05 compared to the untreated control. The scale bar represents 20 
m. 
 
 
5.10 Influence of AA on intracellular calcium concentration and 
intracellular calcium-regulated vasculogenesis of mouse ES cells 
Previous studies have suggested that changes of the intracellular calcium 
concentration are important for cellular communication and are initiated by several 
cellular interactions (192). Additionally, intracellular calcium has been proposed to 
enhance the secretion of LTs (132). Therefore, we evaluated whether the intracellular 
calcium concentration is regulated by AA, and whether changes of the intracellular 
calcium concentration are involved in AA-regulated vasculogenesis.  
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5.10.1 Impact of AA on intracellular calcium concentration 
In order to investigate the effect of AA on the intracellular calcium concentration, 
we assessed intracellular calcium upon AA treatment at different times of cell culture. 
ES cells were induced for differentiation until one day before intracellular calcium 
measurement. On the previous day, EBs were dissociated into single cells and plated 
onto cover slips. On the day of calcium measurement, plated cells were incubated with 
10 M fluo-4, AM with or without BAPTA-AM (10 M) in serum free-medium for 30 min 
and then switched back to normal fresh medium. The intracellular calcium concentration 
following treatment with AA (100M) was measured on day 2, day 4, day 6 and day 8 of 
differentiation.  
 
 The data showed that the percentage of cells displaying intracellular calcium 
transients upon treatment with AA increased from day 2 (approximately 10%) to day 4 
(approximately 14%) and decreased at later stages of differentiation (Figure 5.20). To 
investigate whether calcium from intracellular stores is involved in the AA-mediated 
calcium response, cells were pre-incubated for 30 min with the intracellular calcium 
chelator BAPTA-AM. As shown in figure 5.21 this treatment completely abolished the 
calcium signal elicited by AA, indicating calcium release from intracellular stores.  
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Figure 5.20 Number of cells showing calcium signals upon treatment with AA. 
Intracellular calcium changes upon treatment with AA were assessed on day 2, day4, 
day 6 and day 8 of differentiation. Single cells isolated from EBs were loaded for 30 min 
with fluo-4, AM (10 M). AA treatment elicited calcium responses in approximately 10 % 
of positive cells on day 2 and 14 % on day 4. During subsequent days the percentage of 
responding cells decreased to approximately 7% on day 8 (n = 3). *p < 0.05 compared 
to intracellular calcium concentration on day 2 of differentiation. 
 
A) 
 
 
B) 
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Figure 5.21 Representative tracings of intracellular calcium responses upon 
treatment with AA. Isolated single cells were plated on cover slips on day 3. On day 4, 
cells were pretreated for 30 min with fluo-4, AM (10 M) either in the presence (A) or 
absence (B) of BAPTA-AM (10 M). Subsequently, the cells were switched back to fresh 
medium and intracellular calcium was recorded. A) In the presence of BAPTA-AM, AA 
(100 M) failed to increase intracellular calcium concentration. B) In the absence of 
BAPTA-AM, AA transiently increased intracellular calcium concentration in single cells 
isolated from EBs. (n = 3) 
 
5.10.2 Effect of intracellular calcium on PECAM-1 and VE-cadherin expression 
The data of the previous experiment (5.10.1) demonstrated that AA raised the 
intracellular calcium concentration in differentiating ES cells. To investigate whether 
these changes in intracellular calcium are necessary for the stimulation of 
vasculogenesis achieved by AA, we cultivated EBs from day 3 to day 10 of 
differentiation with AA (100 M) either in the presence or absence of BAPTA-AM (10 
M). On day 10, EBs were collected and the expression of PECAM-1 and VE-cadherin 
was analyzed by western blot technique. It was evident that BAPTA-AM did not inhibit 
the increase of PECAM-1 and VE-cadherin expression achieved upon treatment with 
AA alone, suggesting that the intracellular calcium response was not required for the 
stimulation of vasculogenesis upon AA treatment (Figure 5.22).  
 
A) 
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Figure 5.22 Effect of intracellular calcium on PECAM-1 and VE-cadherin 
expression. EBs were treated with BAPTA-AM (10 M), AA (100 M) or pre-treated 
with BAPTA-AM (10 M) for 1 h and then AA (100 M) from day 3 to day 10 of 
differentiation. A) The representative western blots showed that PECAM-1 expression in 
AA-treated EBs was increased in comparison to the untreated control. PECAM-1 
expression in BAPTA-AM-treated EBs was not changed compared to the untreated 
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control. In the presence of BAPTA-AM AA still increased PECAM-1 expression. The bar 
charts demonstrated that the PECAM-1 expression of the AA-treated EBs were 
significant increased. In AA and BAPTA-AM co-treated EBs PECAM-1 expression 
remained elevated (n = 4). B) The representative western blots and bar charts showed 
VE-cadherin expression in EBs treated with AA was increased in comparison to the 
untreated control. BAPTA-AM treatment had no obvious effect on VE-cadherin 
expression in EBs in comparison to the untreated control. VE-cadherin expression of 
EBs pre-treated with BAPTA-AM and then AA was increased compared to 
BAPTA-AM-treated EBs but no significant change in comparison to the AA-treated EBs 
was observed. The bar charts suggested that the VE-cadherin expression of the 
AA-treated EBs was significantly increased. In AA and BAPTA-AM co-treated EBs still 
significant increased VE-cadherin expression was observed (n = 4). *p < 0.05 compared 
to the untreated control. #p < 0.05 compared to BAPTA-AM treated EBs.  
 
5.10.3 Impact of calcium for AA-mediated vasculogenesis 
To further clarify whether the change of intracellular calcium concentration upon AA 
treatment affects ES cell vascular differentiation, branching points of EBs were 
examined. Consistent with result 5.10.2 branching points of BAPTA-AM-treated EBs 
remained unchanged compared to the untreated control. When EBs were pre-treated 
with BAPTA-AM and then incubated with AA an increased number of branching points 
compared to BAPTA-AM-treated EBs (Figure 5.23) was observed, suggesting that the 
calcium response elicited by AA was not necessary for the stimulation of 
vasculogenesis.  
 
Aa) 
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B) 
 
 
 89 
Figure 5.23 Impact of calcium for AA-mediated vasculogenesis. In order to 
investigate whether intracellular calcium changes elicited upon AA treatment are 
involved in vasculogenesis, EBs were treated with AA (100 M), BAPTA-AM (10 M) or 
pre-treated with BAPTA-AM (10M) for 1 h and then AA (100 M) from day 3 to day 10 
of differentiation. Whole EBs were collected for branching point analysis. Aa) The 
representative images showed that branching points of EBs were increased in 
comparison to the untreated control. Ab) The number of branching points of EBs treated 
with BAPTA-AM did not significantly change compared to the untreated control. 
Branching points of EBs pre-treated with BAPTA-AM and then AA were increased 
compared to BAPTA-AM-treated EBs. B) The bar charts showed the significantly 
up-regulated branching points in AA-treated EBs compared to the untreated control. In 
BAPTA-AM co-treated EBs the number of branching points was still significantly 
increased in comparison to EBs treated with BAPTA-AM alone. The upper panel shows 
representative images of EBs labeled with anti PECAM-1 antibody. The scale bar 
represents 300 m. The bar chart represents mean ± SD of 3 separate experiments in 
which at least 30 individual EBs were analyzed. *p < 0.05 compared to the untreated 
control. #p < 0.05 compared to BAPTA-AM treated EBs. 
 
 
5.11 Role of ROS in AA-induced vasculogenesis of mouse ES cells 
ROS arising in inflammatory processes can stimulate cell proliferation and 
differentiation (143). In the LT signaling pathway, AA and its metabolites have been 
shown to play a role as ROS inducers (152). Hence, we supposed that ROS may be 
involved in AA-induced vasculogenesis. To understand whether ROS participate in 
vasculogenesis stimulated by AA, the free-radical scavengers VAS2870, NMPG, and 
Trolox were used to inhibit ROS production during ES cell differentiation. First, the 
ability of AA to induce ROS production was examined. EBs were treated with AA (100 
M) on day 4 for 0.5 h, 1 h, 2 h, 4 h, 6 h or 20 h and ROS production was measured by 
confocal laser microscopy (Leica LCSM TCS-SP2). Second, the influence of 
AA-induced ROS production on vasculogenesis was investigated by applying 
free-radical scavengers to differentiated EBs before assessing the branching points.  
  
 90 
5.11.1 AA induces ROS production in a time-dependent manner 
The representative images showed that ROS production was induced by AA in a 
time-dependent manner (Figure 5.24). Compared to the untreated control, ROS 
production in EBs treated with AA was significant increased following 2 h, 4 h and 6 h 
post-AA treatment and remained on an elevated level until 20 h of incubation with AA.  
 
A) 
 
 
 
 
B) 
 91 
 
 
Figure 5.24 AA induces ROS production in a time-dependent manner. On day 4 of 
differentiation, EBs were treated with AA (100 M) for 0.5 h, 1 h, 2 h, 4 h, 6 h and 20 h, 
and then the ROS fluorescence indicator H2DCF-DA was applied for 30 min. A) 
Representative images showed that ROS production was increased upon treatment 
with AA in a time-dependent manner. B) The statistic analysis indicated that ROS 
production increased significantly after AA treatment for 2, 4, and 6 h and remained on 
an elevated plateau after 20 h of AA treatment in comparison to the untreated control. 
The scale bar represents 300 m (n = 3). *p < 0.05 compared to the untreated control. 
 
5.11.2 Effect of AA-induced ROS production on vasculogenesis  
 Based on the result above, we provided evidence that AA is able to induce ROS 
production in a time-dependent manner. To further understand whether AA-induced 
ROS production also participates in vasculogenesis, whole EBs were collected on day 
10 of differentiation and branching points were examined. On day 3, EBs were treated 
with either AA (100 M) or two different ROS scavengers (NMPG (100 M) and Trolox 
(100 M)) or the NADPH oxidase inhibitor VAS2870 (50 M), respectively, or a 
combination of ROS scavengers, NADPH oxidase inhibitor and AA until day 10 of 
differentiation. As shown in figure 5.25, the branching points of EBs treated with ROS 
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scavengers together with AA were significantly decreased in comparison to that of 
AA-treated EBs (Figure 5.25). Comparable results were obtained upon treatment with 
VAS2870. Notably, ROS scavengers as well as VAS2870 significantly decreased 
branching points already in the absence of AA. Taken together, ROS can be produced in 
response to AA treatment and AA-induced ROS generation is involved in 
vasculogenesis. 
 
Aa) 
 
 
Ab) 
 
 
Ac) 
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Figure 5.25 Effect of AA-induced ROS production on vasculogenesis. EBs were 
treated from day 3 to day 10 of differentiation with AA (100 M) either in presence or 
absence of ROS scavengers (NMPG (100 M) and Trolox (100 M)) or the NADPH 
oxidase inhibitor VAS2870 (50 M). The branching points of vascular structures were 
examined on day 10. A) The representative images showed that branching points of 
AA-treated EBs were significantly increased, while branching points of ROS scavenger 
and NADPH oxidase inhibitor treated EBs were decreased compared to the untreated 
control. B) The bar charts showed the significantly decreased branching points in NMPG, 
Trolox or NADPH-treated EBs compared to the untreated control. The branching points 
in NMPG, Trolox or the NADPH-co-treated EBs were significant reduced in comparison 
to the AA alone. The upper panel shows representative images of EBs labeled with anti 
PECAM-1 antibody. The scale bar represents 300 m. The bar chart represents mean ± 
SD of 3 separate experiments in which at least 30 individual EBs were analyzed (n = 3). 
*p < 0.05 compared to the untreated control. #p < 0.05 compared to AA treated cells. 
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6. Discussion 
Blood vessel formation including vasculogenesis and angiogenesis is the most 
necessary event during embryo development for maintaining homeostasis and survival. 
In addition, blood vessel formation is associated with inflammation in wound healing and 
tumor growth (154). Inflammation, which can be divided into acute inflammation and 
chronic inflammation, is not only a physiological but also a pathological response to 
injury and pathogen infections to cells and tissues inside the body. During inflammation 
immune cells such as leukocytes are recruited to the inflamed tissues for pathogen 
elimination (109). Short period acute inflammation is characterized by leukocyte 
accumulation in the injury region, removal of the inflammatory stimulus and tissue repair, 
while chronic inflammation coincides with continuing and long-lasting inflammation and 
tissue destruction before tissue repair can occur (193). LTs, one class of inflammatory 
mediators, have been previously reported to regulate inflammation by enhancing protein 
production and leukocyte accumulation, promoting permeability of vessels and smooth 
muscle constriction (194; 195). Moreover, novel studies have pointed out that LTs also 
play key roles in vasculogenesis. Previously it has been indicated that the receptors of 
LTB4, BLT1 and BLT2, are involved in regulating endothelial cell proliferation, 
differentiation and migration (56; 57). However, more evidence is required to confirm the 
effect of LTs to modulate vasculogenesis and leukocyte differentiation. Therefore, the 
specific aim of this thesis was to investigate whether the AA/LT signaling pathway could 
contribute to vasculogenesis and leukocyte differentiation.  
 
Based on our result (5.1, 5.2, 5.8 and 5.9) the AA/LT signaling pathway indeed 
plays a role in both vasculogenesis and leukocyte differentiation. Result 5.3 indicated 
that AA-induced vasculogenesis is FLAP-dependent. Result 5.4, 5.5 and 5.6 provided 
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evidence that LTB4, 12(S)-HETE, LTD4, and their corresponding receptors participate in 
vasculogenesis. Last but not the least, as common intracellular signaling factors, ROS 
but not intracellular calcium involve in the stimulation of vasculogenesis achieved by AA. 
Taken together, our findings suggest that the AA/LT signaling pathway contributes to 
vasculogenesis and leukocyte differentiation from ES cells. 
 
Regulation of vasculogenesis by AA 
AA can be synthesized by human cells or taken-up from diet. Imbalanced AA levels 
are found to be related with the occurrence of Alzheimer’s disease, coronary artery 
disease and chronic inflammation (196; 197). According to previous studies, there are 
three main pathways of AA metabolism: the LO pathway, the COX pathway and the 
cytochrome P450 pathway. In the LO pathway, 5, 12 and 15 HPETE and their 
metabolites are produced, while in the COX pathway, PGH2 and its metabolites are 
synthesized. In the cytochrome P450 pathway, four epoxyeicosatrienoic acids (EETs), 
including 5,6-, 8,9-, 11,12-, and 14,15-EETs, are generated (198). Due to our specific 
interest on the regulation of vasculogenesis and leukocyte differentiation by LTs, we 
mainly focused on 5-LO signaling pathway in this project. 
 
Previous studies have demonstrated that AA facilitates cell differentiation of 
adipose tissue, decidual cells and neuronal cells (199-201). However, some of the 
AA-dependent cell commitments are mediated through other AA metabolites such as 
15-LO (202). To date, the impact of LTs on regulating vascular formation is still poorly 
understood. Hence in this study we analyzed how LTs modulate vasculogenesis by 
examining the influence of LT receptor inhibition on LT signaling pathways in order to 
clarify which signaling cascade plays a role in vasculogenesis. Before further 
investigation with specific AA metabolites we firstly confirmed with exogenous AA 
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treatment that AA successfully stimulated vasculogenesis and the expression of 
PECAM-1 and VE-cadherin (results 5.1).  
 
Selection of FLAP inhibitors 
5-LO is the enzyme initiating the AA/LT signaling pathway in bone marrow (203). 
Additionally, FLAP is the key player in AA to 5-LO conversion and enhances the 5-LO 
signaling pathway. There are several kinds of FLAP inhibitors each of which has its own 
distinguishing feature. The most common inhibitor of FLAP is MK886. However, MK886 
is also an antagonist of PPAR, which is one of the receptors of LTB4 (204). To prevent 
cross-interference and to obtain better specificity, we used AM643 and REV5901 as 
FLAP inhibitors. AM643 directly and specifically inhibits FLAP expression. REV5901 is a 
FLAP inhibitor as well as inhibitor of CysLTs receptors, 5-LO and LTs (205). In result 5.2, 
we found that FLAP inhibitors did not fully suppress vasculogenesis. We speculated that 
this might be due to the complex and complementary regulatory networks of 
vasculogenesis, among which the FLAP-regulated AA/LT signaling pathway plays a 
partial but still important role. 
 
Regulation of vasculogenesis by FLAP 
LTs in the cells are converted from membrane-released AA, mainly from pulmonary 
and vascular tissues (206). LT formation requires FLAP for enhancing AA binding to 
5-LO. Due to the significance of AA under physiological and pathological conditions, 
dysfunction of FLAP is related to Alzheimer’s disease, allergy, metabolic syndromes, 
respiratory and cardiovascular disease (207-210).  
 
In this project, we used FLAP inhibitors to examine the effect of FLAP on the LT 
signaling pathway and on the pathway mediating vasculogenesis. Result 5.2 showed 
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that blocking FLAP expression not only suppressed vasculogenesis, but also 
down-regulated the expression of the endothelial markers PECAM-1 and VE-cadherin. 
Additionally, result 5.3 proved that the stimulation of vasculogenesis by AA is dependent 
on the FLAP-enhanced AA/LT signaling pathway. However, FLAP inhibition could not 
fully abolish AA-regulated vasculogenesis. This may be due to the fact that FLAP is 
required for LT synthesis from endogenous AA but it is not essential for LT synthesis 
from exogenous AA (211). When cells encounter FLAP deficiency, the endogenous AA 
conversion is stopped, yet the conversion of exogenous AA from other cells is remained 
and capable of enhancing vasculogenesis. Exogenous AA, derived from plasma or 
neighboring cells and endogenous AA are metabolized through two distinct signaling 
pathways, in which exogenous AA has the preference to produce LTA4 and then convert 
to LTC4 instead of LTB4 in the case of endogenous AA (212). 
 
LTB4 and vasculogenesis 
Previous studies have shown that LTB4, one of the LT-derived inflammatory 
mediators derived from AA, involves in the inflammatory response through promoting 
trans-endothelial migration of neutrophils in vitro (213). In vivo, LTB4 enhances the 
permeability of blood vessels and triggers neutrophil adhesion and consecutive 
migration across microvessel walls (214; 215). In addition, LTB4 has been proven to 
promote differentiation and proliferation of osteoclasts and neuronal stem cells (216; 
217). In our study, we deciphered whether LTB4 takes part in vasculogenesis of ES cells. 
Thus inhibitors of LTB4 receptors, U75302 and LY255283, were separately applied. We 
observed that LTB4 restored the level of vasculogenesis after FLAP inhibition (result 
5.4.1 and 5.4.4). Regarding endothelial markers, LTB4 also restored the expression of 
both PECAM-1 and VE-cadherin, which were decreased by FLAP inhibitors. Additionally, 
in result 5.5 both U75302 and LY255283 inhibitors down-regulated vascular structure 
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formation, which suggests that LTB4 is pivotal for this process. Since another ligand of 
BLT2 receptor, 12(S)-HETE, is from another signaling pathway of AA and is as inducible 
as LTB4 by VEGF, we postulated that 12(S)-HETE would exert similar effect as LTB4 in 
mediating vasculogenesis (218). We found that 12(S)-HETE partially restored 
vasculogenesis after FLAP inhibition, but without reaching statically significance (result 
5.4.4). This might result from that the low stability of 12(S)-HETE in the cell culture 
medium. In addition, Klampfl T, et al. previous demonstrated that 12(S)-HETE inhibition 
can promote clonogenicity, which implied that 12(S)-HETE might have negative effect 
on cell proliferation (219). 
 
CysLTs and vasculogenesis 
CysLTs include LTC4, LTD4 and LTE4, which contain cysteine and are able to 
induce inflammatory reactions. LTD4 and LTE4 are metabolites of LTC4, which is highly 
expressed in differentiated human U937 monoblast leukemia cells incubated with 
dimethyl sulfoxide (220). While LTD4 has been known to be required for 
granulocytic differentiation, the influence of LTE4 on cell differentiation is still unknown 
(221). CysLTs can bind to at least three different types of receptors including CysLT1 
and CysLT2, both of them have high affinity for LTD4. To investigate whether CysLTs 
play roles in vasculogenesis we treated differentiating ES cells with exogenous LTD4. 
We observed that the inhibitory effect of AM643 on PECAM-1 and VE-cadherin 
expression could be restored by exogenous LTD4 in the EBs. This was not the case 
when cells were treated with REV5901 since REV5901 is also an antagonist of CysLTs 
receptors. 
  
BAYu9773, a specific antagonist of CysLT2 was used to further analyze the impact 
of LTD4 on vasculogenesis. BAYu9773 decreased expression of endothelial markers in 
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comparison to untreated control cells. This may indicate that CysLTs especially LTD4 
take part in AA-induced vasculogenesis. 
 
Combination of three LT receptor inhibitors 
 To underscore that LTs regulate vasculogenesis, we combined the use of three 
inhibitors, U75302, LY255283 and BAYu9773. Combined treatment of all three inhibitors 
of LT receptors inhibited AA-induced vasculogenesis and the expression of PECAM-1, 
VE-cadherin and Flk-1 stronger than each inhibitor alone. This corroborated our finding 
that LTs play crucial roles in AA-induced vasculogenesis. 
 
Involvement of LTs in leukocyte differentiation 
Inflammation induces leukocytes to proliferate and accumulate for defending the 
pathogen invasion. Leukocytes belong to the cellular immune system which protects the 
body from foreign pathogens and microbes. The functions of neutrophils, lymphocytes 
and monocytes all require the initiation of leukocyte adhesion and migration through the 
blood vessel wall (222; 223). Leukocyte adhesion is also one of the typical inflammatory 
features. LTs are converted from acute-inflammation-triggered AA release to regulate 
subsequent inflammatory responses by enhancing leukocyte accumulation. For 
characterizing the effect of LTs on leukocyte differentiation, we examined the 
expressions of CD18, CD45 and CD68 as indicators of leukocyte differentiation under 
conditions of exogenous AA treatment and FLAP inhibition. By detecting the levels of 
CD18, CD45, and CD68, we found that AA treatment stimulated leukocyte differentiation 
(result 5.8). On the contrary, FLAP inhibition decreased leukocyte differentiation (result 
5.9). These results indicate that AA/LT signaling pathway involves in leukocyte 
commitment from ES cells. 
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Intracellular calcium changes are not required for AA induced vasculogenesis 
Calcium is essential in human body and acts as an intracellular signaling 
messenger to promote muscle contraction, bone formation and hormone release. 
Extracellular calcium binds to calcium receptors to initiate the differentiation of human 
keratinocytes and HL-60 cells (224-227). Moreover, intracellular calcium plays a central 
role in enhancing the process of AA-induced breast tumour cell proliferation and 
tubulogenesis (228). Since we observed a transient increase of intracellular calcium in a 
subpopulation of differentiating ES cells we investigated whether intracellular calcium 
changes would underlie the stimulation of vasculogenesis observed upon AA treatment. 
We therefore treated differentiating ES cells in presence of the calcium chelator 
BAPTA-AM and assessed endothelial cell marker expression and capillary branching 
structures. However, we observed that under these conditions AA still stimulated 
vasculogenesis which precludes that calcium plays a role in this process. On the other 
hand, calcium has been shown to be involved in LT synthesis. Extracellular calcium can 
promote AA conversion and LT release in macrophages and neutrophils (132). 
Intracellular calcium also promotes LTB4 synthesis, but the optimal intracellular calcium 
concentrations to enhance LT synthesis are between 150 nM and 350 nM (229). In our 
experiments intracellular calcium concentrations upon treatment with BAPTA-AM 
amounted to about 50 nM, while exogenous AA increased the intracellular calcium 
concentration to more than 400 nM, which is not within the optimal range for promoting 
LTB4 synthesis. Furthermore, LTB4 synthesis from high concentrations of exogenous AA 
is independent of intracellular calcium levels since AA can be induced even in the 
absence of intracellular calcium (230; 231). 
 
Involvement of ROS in vasculogenesis stimulated by AA 
 ROS arise from daily oxygen metabolism within the mitochondrial respiratory chain, 
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especially complex I and III, which generate ROS during electron transfer (232). 
Moreover, there are other enzymes within mitochondria including monoamine oxidase 
(MAO) and glycerol-3-phosphate dehydrogenase (GPDH) that can produce ROS (233). 
Several antioxidants such as vitamin C and E act as ROS scavengers to prevent cell 
damage from ROS (234). In the stem cell niche of the bone marrow, a low-oxygen 
environment causes stem cells to escape from ROS effects and maintain self-renewal 
ability (235). However, AA may destroy the function of mitochondria and increase ROS 
production (236). By interfering with the formation of cytochrome c in mitochondria, AA 
stimulates superoxide anion generation and more ROS release (237). Consistent with 
previous findings, we also demonstrated that AA treatment in differentiating ES cells 
raised intracellular ROS levels. Previous studies have shown that up-regulated NADPH 
oxidases and ROS promote cardiomyogenesis of mouse ES cells (238; 239). ROS were 
also reported to participate in Wnt/β-catenin and metabotropic glutamate receptor 
5-mediated cardiomyogenesis (240; 241). Physiologically, low concentration of ROS 
stimulated proliferation, migration and differentiation as well as vasculogenesis of ES 
cells (242; 243). Pathologically, excess ROS generation reduces vasculogenesis by 
triggering apoptosis and aging of ES cells. Moreover oxidative stress is known to 
promote cardiovascular disorder development especially in the heart (242; 244; 245). To 
unravel the potential impact of ROS for vasculogenesis the capability of AA-induced 
ROS to regulate vasculogenesis was examined. Differentiating ES cells were co-treated 
with AA and either free radical scavengers (trolox or NMPG) or the NADPH oxidase 
inhibitor VAS2870. All these treatments successfully prevented AA-induced 
vasculogenesis in our study. This result implies that ROS participate in AA-mediated 
vasculogenesis. 
 
In conclusion, our study uncovers mechanisms underlying the effects of 
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AA-derived LT synthesis on vasculogenesis and leukocyte differentiation of ES cells as 
well as AA-increased ROS production on vasculogenesis. In our study, AA up-regulates 
vasculogenesis and leukocyte differentiation. Inhibition of FLAP, the pivotal enhancer of 
AA signaling pathway, down-regulates vasculogenesis and leukocyte differentiation. 
Furthermore, AA-derived LTs increase vasculogenesis. ROS production can be induced 
by the treatment of AA and then up-regulates vasculogenesis. However, intracellular 
calcium does not participate in the AA-induced vasculogenesis. Our study provides a 
novel view of AA and LT-regulated signaling on vasculogenesis of ES cells. Furthermore 
our data shed light on the mechanism of blood vessel formation and leukocytogenesis 
under pathological conditions of inflammation and wound healing. 
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Figure 6.1 Scheme of AA-mediated LT generation: After stimulus, AA is released 
from nuclear membranes and combined with FLAP and 5-LO to convert into LTA4. LTA4 
is then converted to either LTB4 by LTA4 hydrolase or LTC4 by LTC4 synthase. After 
binding to their correspondent receptors, LTB4 and LTC4-derived metabolites regulate 
vasculogenesis or leukocyte differentiation. Moreover, ROS, the by-product of the AA/LT 
signaling pathway also takes part in promoting AA-induced vasculogenesis. 
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7. Summary 
Previous studies have shown the close relation between inflammation and vascular 
structure formation (155). LTs are important mediators of inflammation and are derived 
from cell membrane released-AA after the cells are stimulated by inflammatory stress or 
other factors. To shed light on whether LTs involve in vasculogenesis and leukocyte 
differentiation, pluripotent mouse ES cells were used as in vitro model. ES cells can be 
induced to differentiate to several types of cells including endothelial cells and 
leukocytes.  
 
The following experimental results were achieved in the present study: 
 
1) Exogenous addition of AA to EBs from differentiating ES cells dose-dependent 
stimulated vascular structure formation and increased the expression of the 
vascular markers PECAM-1 and VE-cadherin. Furthermore a stimulation of 
leukopoiesis was observed. 
 
2) Inhibition of FLAP which is a key enzyme in LT synthesis with either AM643 or 
REV5901 significantly downregulated vascular structure formation as well as 
expression of endothelial cell markers. Furthermore FLAP inhibition abolished 
leukopoiesis achieved upon treatment with AA. 
 
3) Exogenous addition of AA metabolites, i.e. LTB4 and LTD4 and 12(S)-HETE partially 
restored vasculogenesis inhibited by the FLAP inhibitors AM643 and REV5901.The 
LTB4 receptor antagonist U75302 and the BLT2 receptor antagonist LY255283 
inhibited vasculogenesis and the expression of PECAM-1, VE-cadherin and Flk-1. 
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Comparable effects were achieved using the CysLTs receptor inhibitor BAYu9773. 
Combined treatment of U75302, LY255283 and BAYu9773 exerted additive effects 
on the inhibition of vasculogenesis and the expression of PECAM-1, VE-cadherin 
and Flk-1. 
 
4) AA treatment of differentiating ES cells elicited a transient calcium response in a 
subpopulation of cells. The intracellular calcium response was not related to the 
AA-induced vasculogenic process since chelation of intracellular calcium by 
BAPTA-AM did not abolish vascular structure formation. 
 
5) AA treatment of differentiating ES cells within EB increased intracellular ROS. 
Co-incubation with either free radical scavengers or the NADPH oxidase inhibitor 
VAS2870 abolished ROS generation as well as AA-stimulated vasculogenesis. 
 
Conclusion: 
AA stimulates vasculogenesis and leukopoiesis of ES cells via activation of LT 
signalling pathways and elevation of intracellular ROS. 
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Zusammenfassung 
Frühere Studien haben eine enge Beziehung zwischen entzündlichen Prozessen und 
dem Wachstum vaskulärer Strukturen aufgezeigt. Leukotriene (LT) sind wichtige 
Entzündungsmediatoren und werden aus Arachidonsäure (AA) nach deren 
Freisetzung aus der Membran durch inflammatorischen Stress und andere Faktoren 
gebildet. Um zu erhellen, ob LTs Prozesse der Vaskulogenese und 
Leukozyten-Differenzierung regulieren, wurden pluripotente embryonale Stammzellen 
(ES) der Maus als in vitro Modell verwendet. ES Zellen können zur Bildung 
verschiedener Zelltypen einschließlich endothelialer Zellen und Leukozyten stimuliert 
werden. 
 
In der vorliegenden Studie wurden die folgenden Ergebnisse erzielt: 
 
1) Exogene Behandlung von Embryonalkörperchen (EBs) aus differenzierenden ES 
Zellen mit AA stimulierte Dosis-abhängig die Bildung vaskulärer Strukturen und die 
Expression der endothelialen Marker PECAM-1 und VE-cadherin. Weiterhin wurde 
eine Stimulation der Leukopoiese beobachtet. 
 
2) Inhibition von 5-Lipoxygenase-aktivierendem Protein (FLAP) eines 
Schlüsselenzyms der LT Synthese durch entweder AM643 oder REV5901 
verhinderte die Bildung vaskulärer Strukturen und die Expression endothelialer 
Marker. Weiterhin wurde eine Inhibierung der Leukopoiese erzielt. 
 
3) Exogene Zugabe der AA Metabolite LTB4, LTD4 und 12(S)-HETE revertierte 
teilweise den inhibierenden Effekt der FLAP Antagonisten AM643 und REV5901. 
Der LTB4 Rezeptor Antagonist U75302 und der BLT2 Rezeptor Antagonist 
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LY255283 inhibierten sowohl die Bildung vaskulärer Strukturen als auch die 
Expression der endothelialen Marker PECAM-1, VE-Cadherin und Flk-1. 
Vergleichbare Effekte wurden für den CysLT Rezeptor Inhibitor BAYu9773 
beobachtet. Die kombinierte Behandlung der Zellen mit U75302, LY255283 und 
BAYu9773 führte zu additiven Effekten bei der Inhibition der Vaskulogenese und 
der Expressionsverminderung von PECAM-1, VE-Cadherin und Flk-1. 
 
4) Behandlung differenzierender ES Zellen mit AA induzierte in einer Subpopulation 
der Zellen eine transiente Kalzium-Antwort. Die intrazelluläre Kalzium-Antwort war 
jedoch nicht mit dem vaskulogenen Effekt von AA korreliert, da 
Kalzium-Chelierung durch BAPTA-AM die AA-vermittelte Vaskulogenese nicht 
beeinflusste. 
 
5) Behandlung differenzierender ES Zellen in EBs mit AA führte zu einem Anstieg 
intrazellulärer Sauerstoff-Intermediate (ROS). Ko-Inkubation mit entweder freien 
Radikalfängern oder dem NADPH Oxidase Inhibitor VAS2870 inhibierte die ROS 
Bildung und die AA-vermittelte Vaskulogenese. 
 
Schlussfolgerung: 
AA stimuliert die Vaskulogenese und Leukopoiese von ES Zellen. Der 
unterliegende Signalweg wird durch LTs und einen Anstieg intrazellulärer ROS 
vermittelt.  
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8. Abbreviations  
5-HPETE 5-hydroperoxyeicosatetraenoic acid  
5-LO 5-lipoxygenase  
12(S)-HETE 12S-hydroxy-5Z, 8Z, 10E, 14Z- eicosatetraenoic acid 
AA Arachidonic acid 
ABCG2 ATP-binding cassette sub-family G member 2 
AFP -fetoprotein 
AM643 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5- 
(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic 
acid 
AP Alkaline phosphatase 
AP1 Activator protein 1  
BAPTA-AM 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis 
BAYu9773 4-[[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentad
ecatetraen-1-yl]thio]-Benzoic acid 
B cells B lymphocytes 
BLT1, 2 LTB4 receptor-1 and 2  
BMP Bone morphogenetic protein  
BSA Bovine serum albumin 
Ca Calcium 
cAMP Cyclic adenosine monophosphate 
CO2 Carbon dioxide 
COX Cyclooxygenase 
cPLA2 Cytosolic phospholipase A2 
Cy5 Indodicarbocyanine 
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CysLTs Cysteinyl leukotrienes 
CysLT1-R CysLT receptor 1 
CysLT2-R CysLT receptor 2 
D-LIF Diffusible form LIF 
DCF Dichlorofluorescein 
DII4 Delta like ligand 4 
DMEM Dulbecco’s modified Eagles medium 
DMSO Dimethyl sulfoxide 
EBs Embryoid bodies 
EC cells Embryonic carcinoma stem cell 
ECL Enhanced chemi-Luminescence 
EDTA Ethylendiamintetraacetat 
EETs Epoxyeicosatrienoic acids 
EG cells Embryonic germ cells 
ERK1, 2 Extracellular signal-regulated kinase 1and 2 
ES cells Embryonic stem cells 
FCS Fetal calf serum 
FGF Fibroblast growth factor 
FITC Fluorescein isothiocyanate 
FLAP 5-lipoxygenase activating protein 
Flk-1 Fetal liver kinase -1 
Fluo,4-AM 1-[2-Amino-5-(2,7-difluoro-6-hydroxy-3-oxo-9-xanthenyl)  
phenoxy]-2-(2-amino-5-methyl-phenoxy)ethane-N,N,N’,N’- 
Tetraessigsäure, pentaacetoxymethyl ester 
Foxa2 Forkhead box protein A2 
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g Gravity 1g = 9,81m/s² 
g Gram 
gp130 Glycoprotein 130  
GPDH Glycerol-3-phosphate dehydrogenase 
h Hour 
H2DCF  2',7'-dichlorodihydrofluorescein  
H2DCF-DA  2',7'-dichlorodihydrofluorescein diacetate 
H2O Water 
H2O2 Hydrogen peroxide 
HCl Hydrogen chloride 
He Helium 
HETEs Eicosatetraenoic acids 
HSC Hematopoietic stem cell 
IgG Immunoglobulin G 
IHC Immunohistochemistry 
IL Interleukin  
IMDM Basal Iscoves modified Dulbecco’s medium 
Lhx1 LIM homeobox 1 
LIF Leukemia inhibitory factor 
LIFRβ Low-affinity LIF receptor 
JAK Janus kinase 
KCl Potassium chloride 
kDa kilo Dalton  
KH2PO4 Potassium phosphate monobasic 
Klf4 Kruppel-like factor 4  
LIF Leukemia inhibitory factor 
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LO Lipoxygenase 
LT Leukotriene 
LTA4 Leukotriene A4 
LTB4 Leukotriene B4 
LTC4 Leukotriene C4 
LTD4 Leukotriene D4 
LTE4 Leukotriene E4 
LY255283 1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]-
ethanone 
M Molar 
M-LIF Matrix–bound form LIF 
MAO Monoamine oxidase 
MAP Mitogen-activated protein  
MEM Minimal essential aminoacids 
Mg Magnesium 
mg Milligramm 
min Minute 
ml Milliliter 
µM Micromolar 
µm Micrometer 
mM Millimolar 
MOPS 3-(N-morpholino)propanesulfonic acid 
Na2HPO4 Sodium hydrogen phosphate 
NaCl Sodium chloride 
NADPH Nicotinamide adenine dinucleotide phosphate 
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Ne Neon 
NEA Non-essential aminoacids  
NFB Nuclear factor kappa-light-chain-enhancer of activated B cells 
nM Nanomolar 
NMPG N-(2-Mercaptopropionyl)glycin 
Oct 4 Octamer-binding transcription factor 4 
PBS Phosphate-buffered saline 
PBST Phosphate-buffered saline and Triton  
PECAM-1 Platelet endothelial cell adhesion molecule 
PFA Paraformaldehyde 
PGH2 Prostaglandin H2 
PMNs Polymorphonuclear neutrophils 
PPARα Peroxisome proliferator-activated receptor alpha 
REV5901 6-(6-(3R-hydroxy-1E,5Z-undecadien-1-zl)-2-pyridinyl)-1,5S-hexanediol 
ROS Reactive oxygen species 
RT Room temperatur 
s Second 
SD Standard deviation  
SDS Sodium dodecyl sulfate 
Ser Serine  
SHH Sonic hedgehog 
Sox2  Sex determining region Y-box 2 
SRS Slow reacting substance 
SRS-A Slow reacting substance of anaphylaxis 
STAT-3 Signal transducers and activators of transcription 3 
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SSEA-1 Stage-specific embryonic antigen  
TBS Tris-buffered saline  
TBST Tris-buffered saline and Tween 20 
T cells T lymphocytes 
TNF Tumor necrosis factor 
Trolox -tocopherol (vitamin E) derivative 
U75302 6-(6-3R-hydroxy-1E,5Z-undecadien-1-yl)-2-pyridinyl)-1,5S-hexanediol 
VAS2870 VAS2870, 3-benzyl-7-(benzoxazolyl)thio- -1,2,3-triazolo[4,5]pyrimidin 
VE-Cadherin Vascular endotheliam cadherin (Syn. CD144) 
VEGF Vascular endothelial growth factor  
VEGFR1, 2 Vascular endothelial growth factor receptor-1 and 2  
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